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Abstract
Radiotherapy uses high doses of energy to eradicate cancer cells and thus destroy the bulk
of tumors. Radiobiologists try to precisely deliver radiation to a targeted area in order to
maximize the cancer cell kill rate while trying to minimize damage to normal cells. To
achieve this goal, various treatment schedules have been developed, but there still remain
significant obstacles to improving the effectiveness of these schedules. It has been observed
that various factors play important roles in the effectiveness of treatment. One important
factor is tumor heterogeneity, that is, the genetic and epigenetic variations in tumors. This
cellular diversity can influence the efficacy of radiotherapy due to the different radiosensi-
tivities among cancer cells. In addition, the interplay between this heterogeneous cellular
population and the tumor microenvironment can negatively affect the treatment process.
In this thesis, deterministic and stochastic mathematical models are developed to explore
the role of heterogeneity and the impact of cellular repair on radiotherapy outcomes. The
results suggest that shrinking a tumor is not sufficient to control the disease; the fraction
of cells resistant to treatment must also be reduced. In addition, supposedly optimal treat-
ment schedules can lead to markedly different results even in patients with the same type
of cancer, due to cellular and microenvironmental differences among tumors. Therefore,
based on these variations, it is important to design new therapeutic approaches for each
cancer type and even each patient. The modified Gillespie algorithm for discontinuous time
changing rates is applied to explore the impact of plasticity, as well as random demographic
factors on the tumor control probability. The random modification of tumor microenviron-
ment is shown to influence the efficiency of radiotherapy. Increasing the standard deviation
v
leads to an initial rise in the tumor control probability, which thereafter drops over time
if a tumor is not eradicated entirely. The results also confirm that plasticity in a tumor
reduces the tumor control probability, especially in highly resistant tumors. In addition,
in the presence of plasticity, combining radiotherapy with a targeted therapy increasing
the differentiation of CSCs does not increase the probability of CSC and tumor removal
greatly. Finally, the impact of regulatory negative feedback on the sphere formation po-
tential of a single CSC is explored. The sphere formation efficiency and average sphere
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Cancer is a highly complex disease that involves uncontrolled growth of abnormal cells and
often results in the death of the host. Although an incredible amount of effort has been
expended in trying to understand the process of angiogenesis, as well as the initiation,
progression and evolution of malignancies, our knowledge of the fundamental mechanisms
still leaves much to be desired. The original cause of cancer is believed to be the molecular
events that lead to the accumulation of genetic or epigenetic mutations in normal cells.
The majority of these genetic instabilities correspond to the upregulation of oncogenes
and inactivation of suppressor genes or gate keepers, which interrupt cellular functions
and prompt tumorigenesis (Sjöblomet al., 2006). In addition, cancer cells are subject to
ongoing evolution and mutation. In fact, tumors consist of genetically diverse cellular pop-
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ulations, presenting different phenotypic features with differing cell surface receptors, and
proliferative, angiogenic and metastatic strength. One suggested prospective on this di-
versity is given by the cancer stem cell (CSC) hypothesis, which explains the intratumoral
heterogeneity arising from the symmetric and asymmetric division of CSCs, regenerating
themselves and giving rise to their offspring. The interaction between heterogenous ma-
lignant cells, with their aberrant microenvironment, can increase aggressiveness and the
emergence of treatment resistance in tumors. Although exposure to most available cell-
kill agents results in tumor bulk shrinking, the resistant tumor cells remain unaffected.
Therefore, it is important to study the role and impact of tumor heterogeneity and the
microenvironment on therapeutic approaches.
In this thesis, a mathematical model is used to study the effect of tumor heterogeneity
on radiotherapy outcomes. In addition, the impact of random microenvironments on tumor
control is investigated using stochastic simulations. Chapter 2 presents a comprehensive
literature review of mathematical models exploring the specific role of CSCs in treatment.
Thus, this introduction is limited to a general overview of relevant biological information.
1.2 Tumor heterogeneity, CSCs, and microenviron-
ments
The characteristics and features of tumors change based on their site and cell of origin.
These variations also exist for the same cancer in an individual (Heppner, 1984). In general,
the cellular population within tumors are both phenotypically and genotypically heteroge-
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nous as a result of genetic and epigenetic changes. Clonal evolution theory posits that
the accumulation of these modifications in a single cell can lead to malignancy, and over
time, leads to heterogeneity within tumors. The more recent CSC hypothesis proposes a
hierarchical model in which CSCs sit at the apex, and have a tumorigenic ability to repro-
duce themselves and their progeny (Meacham & Morrison, 2013; Shackleton et al., 2009).
Recently, it has also been observed that there is a degree of bidirectionality, as a result of
plasticity among cancer cells. This suggests that non CSCs have the capacity to display
cancer-stem cell like behavior and posses higher tumorigenic potential (Marjanovic et al.,
2013b). Experimental observations have been able to identify CSCs in different types of
cancers ranging from leukemia, breast, colon, CNS, to head and neck cancers (Schatton et
al., 2009, and references therein). However, it is difficult to determine the fraction of CSCs
in a tumor due to the lack of perfect biomarkers for CSCs and due to the phenomena of
plasticity.
CSCs and cellular heterogeneity are linked with tumor progression, treatment resis-
tance, and metastasis. On the other hand, the tumor microenvironment also has a signifi-
cant impact on the initiation and propagation of tumors, in addition it can trigger cellular
diversity among cancer cells (Rich et al., 2016). The tumor microenvironment is a highly
variable and complex structure that regulates the connection among cancer cells, normal
cells, abnormal vascular system and signaling pathways. The formation of irregular vascu-
lar networks, which occurs through angiogenesis, leads to the aberrant of erratic transport
of oxygen and nutrition to the tumor cells. This variable blood flow results in metabolic
changes, high interstitial fluid pressure, hypoxia, and acidosis, all of which contribute to
treatment resistance and metastatic potential (Trédan et al., 2007). For example, there
3
is a decrease in the proliferation of cancer cells under conditions of nutrition shortage.
The cells move into a quiescent state (cell cycle arrest) and become resistant to thera-
peutic approaches. In addition, hypoxia is believed to be correlated with the induction
of angiogenesis and cell survival, as well as with changing biochemical pathways, leading
to treatment resistance (Trédan et al., 2007). Therefore, a better understanding of the
impact of tumor heterogeneity and the tumor microenvironment on cancer evolution is
necessary in order to develop appropriate treatment strategies. In this frame work, it is
highly desirable to investigate the role and impact of intatumoral variation and arbitrary
microenvironments on treatment efficiency.
1.3 Radiotherapy
Radiotherapy is one type of cancer treatment that can be prescribed as a single agent
or in combination with other therapeutic strategies (such as chemotherapy, surgery, and
immunotherapy). Originally, the treatment was delivered as a large single dose, which
caused many complications and toxicities. Later, smaller fractions of radiation were ad-
ministered over a period of several weeks, (a process called fractionated radiotherapy), to
reduce radiotherapy-induced complications (Mitchell, 2013; Pajonk et al., 2010). To un-
derstand the idea behind fractionated radiotherapy, it is important to study cellular death
due to radiation.
In general, radiation damages critical targets such as the DNA of cells, resulting in
mutation or cellular death through apoptosis and necrosis if cells fail to repair the damage.
The biological effects of radiation on DNA can be both direct or indirect. In the former,
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radiation interacts with DNA directly; indirect effects are due to the ionization of water and
other molecules in the cells, which generate free radicals that are able to diffuse and alter
DNA (Cox & Ang, 2009; Hall & Giaccia, 2006). The radiation-induced damage leads to a
number of DNA lesions, resulting in single strand breaks that usually arise from exposure
to smaller doses of radiation, and double strand breaks that are mostly responsible for
cellular death and chromosomal aberrations.
The outcome of fractionated radiotherapy depends on the DNA repair mechanism,
redistribution of cancer cells in the cell cycle, and repopulation and reoxygenation of cells
between fractions (Pajonk et al., 2010). The main cause of radiation induced cell death is
the production of lethal damage such as double strand breaks in the DNA, which mainly
occurs at higher doses of radiation. Yet, the majority of damage to the DNA is sublethal
and can be repaired at lower doses. However, exposure to fractions of lower doses of
radiation can lead to the accretion of sublethal lesions contributing to destruction but
with lower toxicity to normal tissues (Mitchell, 2013).
The response of cells to radiotherapy depends on their stage in the cell cycle. The cell
cycle is a sequence of events leading to cellular division. It consists of four major phases G1,
S, G2, and M . In this process, cells expand in size and DNA control mechanisms monitor
and initiate any repairs needed during DNA synthesis (G1). Replication of DNA (S) follows
with further DNA check points and repair as required (G2). Finally, cellular growth stops
and cellular division is complete (M). Commonly, cells in the late synthesis phase (S) are
more radioresistant, and cells in late G2 or mitosis (M) are more readiosensitive (Otani
et al., 2016). Fractionation prepares surviving cells to move forward in the cell cycle into
more radiosensitive stages, where they can be targeted in the next fraction of treatment.
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Both normal and cancer cells show an increase in cellular proliferation after exposure
to radiation. This can be a potential benefit of fractionated radiotherapy, since quick
cellular proliferation can raise the number of damaged cells in the mitosis phase and so
increase radiosensitivity and cellular death. However, for prolonged radiation protocols,
the efficiency of downstream doses of fractions might diminish due to accelerated cellular
division. In addition, applying larger doses of radiation can increase toxicity and necessitate
stopping the treatment process for (Mitchell, 2013).
Hypoxic tumors are more radioresistant, and lack of oxygen has been shown to be
linked to better repair rates. In fact, the presence of oxygen can generate permanent
damage (through oxygen fixation), increasing cellular kill (Cox & Ang, 2009). The oxygen
level changes continuously in tumor microenvironments, and the hypoxic regions can be
categorized into two different groups, chronic and acute. Chronic hypoxia occurs in regions
beyond the limit of oxygen diffusion from the vascular system, but acute hypoxia occurs in
regions where there is temporary disruption of oxygen diffusion (Bayer & Vaupel, 2012).
The gap between radiation fractions is assumed to allow reoxygenation among cancer cells,
which increase radiosensitivity to the radiotherapy.
Radiotherapy protocols have improved with advancing technologies. Today’s better-
designed regimens allow tumors to be targeted with precision and reduce the risk of normal
tissue complications. For example, in addition to conventional schedules, which deliver a
fraction of the total radiation daily, hyperfractionated and hypofractionated protocols have
been suggested to enhance outcomes. The hyperfractionated strategy consists of two or
three fractions per day with small doses of radiation, decreasing late regime toxicity and
increasing total administered doses. In contrast, Hypofractionation shortens treatment
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durations by applying fewer number of fractions but higher doses of radiation per fraction.
Despite recent progresses, however, available therapeutic approaches have not been
successful in most cases. Although the underlying mechanisms are truly complicated and
not well understood, one important reason is the radiation refractoriness of CSCs to ra-
diation. As a result, radiation is more prone to kill differentiated cells than the CSCs,
responsible for driving tumor growth. Basically, CSCs benefit from superior DNA repair
mechanisms with enhanced checkpoint activation that can exacerbate cellular resistance to
radiotherapy (Bao et al., 2006; Wang, 2015). It is also assumed that CSCs are generally
in the quiescent state G0, in which cells stop dividing. This slow cycling subpopulation of
cells displays higher proliferation potency after exposure to fractions of radiation, which
explains the enhanced regeneration of cancer cells after treatment. In addition, stochastic
effects in tumor microenvironments also prompt CSC proliferation. In particular, CSCs
possess greater tumorigenicity in hypoxic conditions (Pajonk et al., 2010; Vlashi et al.,
2009). Therefore, targeting CSCs can be beneficial in developing more efficient radiother-
apy schedules. Moreover, there has been significant effort in treatment planning strategies
to take into consideration personalized therapeutic approaches that account for differences
in genetic backgrounds between individuals, and the heterogeneity and aggressiveness of
their specific tumors.
The effect of fractionated radiotherapy on tumor heterogeneity and the impact of ran-
domness in the microenvironment on tumor control are discussed in Chapters 3 and 4
respectively.
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1.4 Sphere forming assay
A Sphere forming assay is a cell culture technique that hinges on the ability of a single
cell to proliferate and form a sphere (Johnson et al., 2013; Pastrana et al., 2011). This in
vitro technique was initially used to study normal neural stem cells; later, it has since also
been applied to identify the subset of cancer cells that are capable of clonogenic growth
(Stamatakos et al., 2006). One variation known as the mammosphere, has been widely
used for mammary gland cells to investigate mammosphere formation efficiency (MFE),
and to study the effect of radiotherapy and chemotherapy as well as the microenvironment
on MFE (Lagadec et al., 2010; Lonardo et al., 2013).
The first intention of a sphere formation assay is to measure the activity of stem cells
or early progenitor cells. It is usually assumed that each plated cell has the ability to
form a sphere (Turner, 2009a). However, the former assumption has been questioned
by Stamatakos et al. (2006), who showed the existence of migration and fusion between
neurospheres.
Sphere forming assay protocols are usually designed guided by the underlying purpose
of the study, the type of cell line, and the questions that need to be answered by the
experiment. Nonetheless, almost all these procedures have common steps in which spheres
are harvested from single cells appropriately dispersed in a well. Cells are allowed to
grow for a number of days, which is determined based on the cell line and experimental
conditions. Finally, cultures of cells are deemed to be sphere when they exceed a certain
size threshold. Sphere formation efficiency is calculated as below:
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number of spheres per well
number of cells seeded per well
× 100. (1.1)
In this thesis, the mammosphere formation data for a breast cancer cell line is used for
parameter estimation in Chapter 3.
1.5 Thesis objectives
This thesis consists of the following four main chapters that cover the impact of hetero-
geneity and the microenvironment on radiotherapy efficiency. Chapters 2 and 3 are based
on peer-reviewed journal papers published from this thesis work.
1.5.1 Cancer stem cells, the tipping point: Minority rules?
Chapter 2, is a review of mathematical models, studying the impact of CSCs on therapeutic
outcomes and efficiencies. Consequently, the chapter splits into three sections. The first
section addresses the effect of CSCs on chemotherapy and radiotherapy resistance, the
second focuses on the developing of new strategies to raise CSC kill rates, and the final
section discusses the design of optimum treatment regimens based on the CSC hypothesis.
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1.5.2 Mathematical modeling of the effects of tumor heterogene-
ity on the efficiency of radiation treatment schedule
In Chapter 3, a minimal mathematical model is proposed to investigate the impact of
tumor heterogeneity and cell cycle arrest on the outcome of various radiotherapy regimens.
The model parameter values are determined using stochastic and deterministic simulations
applying mammosphere formation efficiency and the fraction of CSCs data on the breast
cancer cell line. The following questions are answered:
• How do different radiotherapy schedules affect the phenotypic heterogeneity of cancer
cell populations, in particular CSCs?
• Is tumor reduction after radiotherapy sufficient to control the disease?
1.5.3 The impact of random tumor microenvironment on tumor
control probability
Chapter 4 analyzes a stochastic framework for studying the impact of random fluctuations
on TCP, which is defined as the probability of cancer cell extinction. The derivation of the
analytical solution is not feasible in all cases, for example, when cellular birth and death
rates change arbitrarily over time. Therefore, a modified Gillespie algorithm is applied to
determine the TCP in the presence of random discontinuous alterations in demographic
rates. We investigate the following questions.
• What is the impact of random fluctuations on TCP?
10
• How does TCP change as randomness increases?
• What is the effect of randomness on extinction time distribution?
1.5.4 The impact of plasticity on tumor control probability
In Chapter 5, a stochastic model is developed based on the CSC hypothesis, to study
the impact of plasticity on TCP. The model considers the time evolution of CSC and
progenitors in the presence of plasticity. Therefore, TCPS and TCPS+P are defined as the
probability of CSC and tumor removal, respectively. Consequently, a modified Gillespie
algorithm is used to evaluate TCPS and TCPS+P , because the derivation of an analytical
solution is not possible when plasticity comes into play. The following questions are studied.
• What is the effect of cellular plasticity on CSC and tumor removal?
• What is the effect of combination therapy, including radiotherapy and targeted ther-
apy designed to increase CSC differentiation, on CSC and tumor removal?
1.5.5 The impact of plasticity and negative feedback regulations
on sphere formation capacity
Chapter 6 explores the impact of negative feedback on CSC division and dedifferentiation
on the sphere formation potential of a CSC. For this purpose, a two compartment model
consisting of a population of CSCs and progenitors is considered, in which the stochastic
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behavior of cellular divisions is studied. Applying a Gillespie algorithm, the sphere forma-
tion efficiency and the average sphere size of a single CSC is measured in the presence of
plasticity. Thus, the following questions are addressed in this chapter.
• How does regulatory negative feedback affect the sphere formation ability of a single
CSC?
• What is the impact of plasticity and negative feedback on sphere formation efficiency?
(i.e. does a decrease in the plasticity rate have a direct impact on sphere formation
efficiency?)
Chapter 7 concludes this thesis, and suggests possible future work.
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Chapter 2
Cancer stem cells, the tipping point:
Minority rules?
Putative studies continue to support the assertion of the cancer stem cell (CSC) hypothesis,
namely that a very small subgroup of a malignant tumor population initiates and drives
tumor growth. These cells are purported to possess similar biological properties to their
normal adult stem cell counterparts. The CSC hypothesis arises from the observation that
tumors like normal tissues have their origin in cells that display potential for self-renewal
as well as the ability to generate differentiated cells of various lineages. In addition, CSCs
have developed basic characteristics that enable them to evade the effects of standard
therapies and these may in fact underly the mechanisms leading to chemo-resistance and
tumor relapse.
In recent years, mathematical and computational modeling have emerged as powerful
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tools in biomedical research that can be used to study biological systems at multiple scales
ranging from molecular processes to cell-cell interactions and how these interactions lead to
changes at tissue and organ levels. In addition to accelerating biomedical research through
computational simulation of physical experiments, modeling can also be used to guide
experimentalists by identifying possible factors and mechanisms underlying the particular
problem being studied; this in turn, may suggest physical experiments that eventually lead
to the resolution of this very problem.
In this chapter, we review mathematical models that explore the role of CSCs in treat-
ment response, in developing chemo and radio resistance, as well as those that suggest new
treatment strategies. In addition, mathematical models that focus on optimal therapeu-
tic protocols will be discussed. The work presented here has been published in the peer
reviewed journal of Current Stem Cell Reports:
Forouzannia, Farinaz, and Sivabal Sivaloganathan. Cancer Stem Cells, the Tipping Point:




Cancer is a group of diseases that involves abnormal cell proliferation in which the inter-
action of cellular mechanisms and the tumor microenvironment imbue some tumor cells
with metastatic potential resulting in the dissemination of malignant cells to other parts
of the body. Tumor heterogeneity is one of the important features that has been observed
in different types of cancers and this has a significant impact on tumor development and
response to treatment. Both the clonal and CSC hypothesis go some way to explaining
the genesis and evolution of this heterogeneity (Marjanovic et al., 2013a; Shackleton et al.,
2009). Cancer clonal evolutionary theory suggests that tumor initiation relies on multiple
mutations occurring in an arbitrary single cell (Nowell , 1976). However, the cancer stem
cell hypothesis proposes that a small sub-population of cells, known as cancer stem cells
(CSCs), are endowed with tumor initiation and propagation potential (Figure 2.1). These
CSCs are able to perpetuate themselves through selfrenewal and to generate non-CSC
progenies through symmetrical and asymmetrical divisions, respectively. Recent evidence
suggests that the transition from CSCs to normal cancer cells is not unidirectional, and
that there is a degree of plasticity between non-CSC and CSC states (Gupta et al., 2011;
Marjanovic et al., 2013b). Such interconversion can arise as a result of genetic modifications
to cancer cells, random mutations or microenviromental effects.
The therapies that patients receive are usually proposed based on the type, the stage
and location of a particular cancerous malignancy, and on the overall health of the indi-
viduals. The most common types of therapeutic interventions are surgery, chemotherapy
and radiotherapy and in practice, a combination of more than one treatment is applied.
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Figure 2.1: Schematic diagram of CSC hypothesis and clonal evolution theory. In cancer
evolution theory, the acquisition of mutations occurs, followed by expansion of the dom-
inant clone (a). But, the CSC hypothesis suggests that CSCs share similar properties to
normal stem cells (SCs) and are responsible for cancer initiation as well as the generation
of non-CSCs (b).
Chemotherapy drugs can target tumor cells in different ways. Generally, these drugs pre-
vent cancer cells from growing and reproducing rapidly through DNA damage; however,
in the process this often results in damage to normal cells, as well. Chemotherapy can
be given before, during and after radiotherapy (referred to as neoadjuvant, concurrent,
and adjuvant respectively). Current conventional radiotherapies also deliver high-energy
beams to tumor tissues, which induce various types of DNA damage and genomic insta-
bility. Some of the resulting types of lesions, such as double strand breaks, are severe
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enough to cause cell apoptosis. However, the majority of treatment failures for different
types of cancers are a direct result of the emergent resistance of cancer cells to conven-
tional therapies, which leaves patients with limited treatment options (Eyler & Rich., 2008;
Mathews et al., 2013). CSCs show higher resistance to available therapies due to upreg-
ulated DNA repair mechanisms. The ability of non-CSCs to reenter the CSC state can
also contribute to poor clinical results. Furthermore, most available treatment strategies
also target cells that are actively dividing, which is not the most efficient way to destroy
CSCs since they are relatively quiescent. In addition, dysregulated signaling pathways
that control CSC self-renewals, including Notch, PTEN, BMI-1, and WNT, are usually
not targeted by current conventional therapies (Boman et al., 2008). Thus, understanding
the tumorigenic potentials and the effective mechanisms that CSCs develop to enhance
their aggressive phenotype, is essential for the development of more efficient and effective
treatment strategies.
Along with the concerted effort that is underway in different branches of science to
combat cancer, mathematical models have also been effectively utilized to probe the un-
derlying mechanisms driving tumor growth and make predictions that can be validated
experimentally (Anderson & Quaranta, 2008; Altrock et al., 2015; Byrne , 2010; Enderling,
2015). For example, mathematical modeling that is grounded in experimental data can
be used to predict therapeutic outcomes and improve clinical results (Altrock et al., 2015;
Dionysiou et al., 2004; Dhawan et al., 2014; Enderling et al., 2009b; Stamatakos et al.,
2006). Mathematical modeling has been extensively used to try and understand cancer on
different scales, but in this chapter particularly we focus on models that try to simulate
and predict the effects of treatment. Hence, a brief review of these types of models will be
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given next.
Earlier seminal work of Norton & Simon (1977, 1986), utilized mathematical modeling
to integrate biological growth information in to treatment scheduling. This led to perhaps
the greatest clinical trial innovation in half a century, and the wide spread acceptance of
the ”Norton-Simon” hypothesis in clinical circles. Norton and Simon proposed that tumor
growth dynamics follows a sigmoidal function during chemotherapy and suggested that
a dense dose protocol would have better outcomes than standard schedules, which has
been clinically verified, for example in (Citron et al., 2003) amongst numerous others. In
addition, a number of mathematical models discussed tissue response to fractionated radio-
therapy treatments with either acute or protracted doses (Dale, 1985; Oliver, 1964; Roesch,
1978). One of the early models in this area was developed by Thames et al. (1984); Thames
(1985) who used it to investigate the dynamics of radiation damage repair. The approach
used a linear quadratic model to describe cell survival, modified to account for incomplete
repairs between fractions (for fractionated acute continuous exposure) and the repair dur-
ing the administration of the fractions (for low dose rate continuous exposure). The linear
quadratic model and its modifications have been considered extensively in the literature,
to simulate the response to radiation exposure. The evolution of resistance before and
during treatment is also one of the first problems that was addressed in the mathemati-
cal modeling of treatment responses (Coldman & Goldie, 1986; Goldie & Coldman, 1983;
Panetta, 1996; Swan, 2013). Coldman & Goldie (1986), and Goldie & Coldman (1983)
proposed a stochastic model to explore the risk of developing resistance during treatment.
The model assumed that sensitive cells can be eliminated upon receiving treatment and
that resistant mutations can occur with a certain given probability. The results imply
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that the probability of resistance (when treatment includes two drugs given sequentially)
depends on the total number of cells and their mutation rates. The authors suggested that
to improve success rates, drugs should be administered as soon as possible after diagnosis.
They proposed that drugs should be given in an alternating fashion rather than sequen-
tially to have a significant impact on the heterogenous cell populations; nevertheless, this
suggestion could not be confirmed clinically (Bonadonna et al., 2004).
In medicine, to proceed from bench to bedside, numerous clinical trials are needed
to determine the best treatment procedure and protocol. In this context, mathematical
modeling can play an important and critical role in the prediction of the most efficient
treatment strategies, thus avoiding unnecessary and often excessive clinical trials. Several
mathematical models have been developed in the literature to establish the most practical
treatment protocols (Foo & Michor, 2009; Martin et al., 1994; Michor et al., 2005). Many
models try to rapidly minimize the total tumor size; however, successfully controlling tu-
mor growth depends critically on reducing effectively both drug sensitive and drug resistant
cells. Some of the early work by Costa et al. (1992) describes the dynamics of a tumor
that includes drug resistant cells. The model aims to efficiently find the optimal treat-
ment schedule by minimizing the total tumor size. The development of better-designed
treatment regimens is still a field of significant research activity; nevertheless, the attain-
able benefits from treatment must still be evaluated and quantified to be of any clinically
relevant significance. The tumor control probability (TCP) is a measure that attempts
to quantify the probability of destroying or removing malignant cells using a variety of
radiation therapy schedules. In order to establish a better formalism for TCP, different
models have been introduced in the literature such as that of Kendal (1998); Munro &
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Gilbert (1961); Tucker et al. (1990); Yakovlev (1993); Zaider & Minerbo (2000). For ex-
ample, one model frequently discussed in the radiation therapy literature is the so-called
Poisson model of TCP (Munro & Gilbert, 1961; Zaider & Minerbo, 2000). This model
assumes that the number of cells that survive radiation has a binomial distribution; and
if the survival probability is small enough, the probability of no malignant cells remaining
follows a Poisson distribution after treatment. However, the model neither captures the
proliferation of cells during treatment nor the stochastic effects. Later, Zaider & Minerbo
(2000) acknowledged the impact of stochastic effects on radiation-induced cell death and
suggested a model based on a simple stochastic birth/death process.
Generally, most of the primary mathematical models are established based on the clonal
evolution theory, where all cells are capable of giving rise to mutants that lead ultimately
to the formation of tumors. However, the emerging CSC hypothesis has become the sub-
ject of theoretical analysis to explore the role of CSCs in tumor response to treatment and
the acquisition of resistance. The main scope of this chapter is to highlight various math-
ematical models that incorporate the CSC hypothesis as well as some of the fundamental
traits of CSCs. These will be discussed in more detail in Sections 2.2, 2.3 and 2.4.
2.2 The roles of CSCs in evolving resistance and tu-
mor response
Despite much improvement in the design of practical cancer therapies, the majority of
patients often develop tumors resistant to standard therapies (Bao et al., 2006; Chen et
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al., 2016; Dean et al., 2005; Pajonk et al., 2010). It may be that conventional cancer
treatments act more efficiently on highly proliferating cells, and thus leave the quiescent
CSCs relatively unscathed . For example, resistance to Imatinib is one of the complications
that can arise for patients treated for chronic myelogenous leukemias (CML), which can
cause initial refractoriness of the disease and relapse. The evolution of resistance from
an exponentially growing cell population was studied using a continuous time branching
process by Iwasa et al. in (Iwasa et al., 2006). The model starts with a single sensitive
cell that can undergo mutations and become resistant to Imatinib. Finally, the probability
of resistance at the time of diagnosis was calculated and it was concluded that a higher
number of cell devisions increases the occurrence of resistant cells. The quiescence of cancer
stem cells is also a critical characteristic that safeguards them from Imatinib. Hence, a
mathematical model has been developed to explore the impact of cellular quiescence on the
dynamics of drug resistance (Komarova & Wodarz, 2007). For a single drug, if the resistant
cells exist before treatment, the quiescent cells do not modify the chance of resistance,
although they can increase the probability of developing resistant mutants when patients
receive a combination of more than one drug with various targets. In fact, the therapy phase
is not important for emergence of mutants since they existed before the diagnosis, but the
dormant cells may delay the time that is required for the therapy to eliminate the tumor
burden. The authors ultimately suggested that reducing the number of quiescent stem cells
during therapy is not beneficial for reduction of resistance risk, since plasticity is another
key factor that contributes to resistance and invasion. Poleszczuk et al. (2016) used a
mathematical model to simulate and investigate the effects of different rates of transitions
(from non-CSCs to CSCs) on tumor growth and treatment response. The results show
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that tumors with low rates of plasticity can regrow after radiotherapy. Nevertheless, for
tumors with high plasticity rates, post therapy cancerous cells undergo remission after
regrowth, because radiotherapy appears to increase CSC depletion. Although the results
seem interesting, more experimental investigation is required, to ensure this is not an
experimental or computational artifact.
Gupta et al. (2011) combines both biological experiments and mathematical simula-
tions to examine the sensitivity of distinct phenotypic states (Stem like, basal, luminal)
to treatment. For this purpose, breast cancer cell lines (SUM159 and SUM149) have been
treated with two conventional chemotherapy drugs: paclitaxel and 5-fluorouracil (5-FU),
which resulted in increasing the portion of cancer stem like cells for both cell lines. To gain
a comprehensive understanding of these results, a Markov model has been established to
examine the dynamics of breast cancer cell populations and transition between different
states. The results indicate that basal cells are more sensitive to paclitaxel in comparison
to the other two states for the SUM159 line. Moreover, the proportion of both stem like
cells and basel cells show approximately a 5 fold increase after receiving paclitaxel, but the
growth in basal cells is due to the resistance of stem like cells to the treatment, which can
reproduce basal cells afterwards. In addition, Gao et al. (2013) demonstrate that resistance
to radiotherapy is not the only critical factor responsible for CSC enrichment in gliomas
and that repeated exposure to radiotherapy can create a microenvironment that tilts the
proliferation in favor of symmetric divisions.
Cell surface protein expression profiles are the main tool used to isolate cancer stem cells
in different tissues. For example, CD34highCD38low, CD133+, and CD44highCD24low
are common biomarkers used for leukaemia and brain and breast tumors, respectively, see
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(Singh et al., 2004) and references there in. However, clearly not all cells that have the same
protein expression are necessarily cancer stem cells, and it appears that both cancer stem
cells and early generations of progenitors often express the same protein markers (Charafe-
Jauffret et al., 2009). These findings have been taken into consideration in developing
a hierarchical model that includes stem cells, the Nth generation of progenitor cells, and
mature cells. Dhawan et al. (2014) have employed a fully stochastic model for a hierarchy of
heterogenous cell populations and used numerical simulations to obtain the tumor control
probability (TCP). The TCP is defined as the probability of eradicating all cancerous cells
in a particular tissue and is used as a measure of radiotherapy efficacy. Based on the
CSC hypothesis, removing CSCs is essential to achieve a cure. Therefore, the probability
of controlling cancer stem cells only (TCPS) was also determined. Furthermore, because
of imperfect biomarkers for CSCs, the probability of eliminating biomarker positive cells
(TCPCD+) was calculated. Finally, it is suggested that TCPCD+ can be a potentially better
clinical alternative for TCPS.
2.3 New therapeutic strategies targeting CSCs
CSCs are generally not targeted by commonly used treatment strategies, so designing ther-
apies that are able to specifically target CSCs is of paramount importance (Koury et al.,
2017; Maugeri-Sacc et al., 2011; Ogawa et al., 2013). For example, it has been shown that
the fraction of CSCs is enriched after radiotherapy due to the highly efficient DNA damage
response in gliomas (Bao et al., 2006). Thus, developing effective treatment strategies that
target and eradicate CSCs is crucial to improving clinical results and minimizing recur-
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rence. Consequently, designing therapies that include both standard anticancer treatments
and CSC-targeting agents may be an effective double pronged attack to eliminate various
types of cancer cells. For instance, Goldman et al. (2015) used both mathematical model-
ing and experimental studies to investigate the mechanisms behind adaptive resistance in
breast cancer patients treated with a high concentration of taxanes. The results indicate
that treatment with taxane leads to a phenotypic cell state transition to the CSC popula-
tion, which can contribute to tumor resistance. Moreover, it is demonstrated that applying
inhibitors that can control the SFK/HcK pathways in a proper temporal schedule (after ex-
posure to taxanes) increases the sensitivity to chemotherapy treatment and thus increases
cell death. Furthermore, a simple mathematical model has been presented (Dingli & Mi-
chor, 2006) to illustrate the importance of eradicating CSCs. The model includes two layers
of differential equations to account for the hierarchy of stem cells and differentiated cells
for both normal and tumor cells. Analysis of different therapeutic possibilities implies that
increasing apoptosis or decreasing the generation of malignant mature cells are not useful
approaches to controlling and removing the disease due to plasticity and replenishment of
CSCs. However, the therapeutic protocols that prevent CSCs from reproduction have the
potential to eradicate the disease if CSCs are subjected to such a therapy for an extended
period of time. Furthermore, it is predicted that agents that either decrease the division
rate or increase the death rate of CSCs can improve the results, however the eradication of
cancerous mature cells is needed to minimize the risk of failure and eliminate the potential
impact of plasticity. Additionally, a mathematical model has been developed based on the
work of Youssefpour et al. (2012) to explore the advantage of ”differentiated” therapies
and radiotherapy combinations, which push CSCs to differentiate into descendants that
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are more sensitive to radiotherapy (Bachman et al., 2013). Consequently, applying ”dif-
ferentiated” therapies along with radiotherapy appears to improve treatment success and
decrease side effects for head and neck, brain and breast cancers.
Piccirillo et al. (2006) have reported that exposure to bone morphogenetic proteins
(BMPs) decreases proliferation and increases the expression of non cancer initiating cells
in glioblastomas (GBMs). This study demonstrated that brain tumor stem cells (BTSCs),
identified by biomarker CD133+, are induced by BMPs to differentiate into CD133− cells,
which are not tumorigenic and are more responsive to conventional cancer therapies. These
findings suggest that adding proteins like BMPs to the currently available radiotherapy
protocols might significantly improve outcomes; nevertheless, more investigation is required
due to other possible interactions in the complicated underlying mechanisms driving tumor
growth. From this perspective, Turner et al. (2009b) have proposed a mathematical model
that represents the effect of BMPs on radiotherapy results for glioblastoma based on the
cancer stem cell hypothesis. The model describes the stochastic effects of the small number
of cells for different types of BTSC divisions, symmetric self-renewal S → S+S, asymmetric
self-renewal S → S + P and symmetric proliferation S → P + P . These two subgroups of
cells can also undergo apoptosis and be discarded. On a larger scale, however, the model
considers the corresponding average equation to study the role of BMPs and the cell kill
response of radiotherapy on tumor dynamics. The model is mathematically given by:
dS(t)
dt





















where ρ̃s(S, P ) = ρs(1 − S/Slim − P/Plim), which employs logistic growth dynamics to
capture the competition between species for limited nutrition. Here, Slim and Plim stand for
the maximum population of BTSCs and progenitors, respectively. Additionally, ρs denotes
a rate of proliferation for stem cells that can occur with probability r = r1 − r3, where r1
and r3 are the probability that BTSCs go through symmetric self-renewal and symmetric
proliferation, accordingly. These two types of cells can undergo apoptosis with probability
Γi (i ∈ {S, P}). In addition to apoptosis, cells can also be removed with radiation dose
dj given at time tj on j
th fraction of treatment. Here, the function f is assumed to be
negative exponential for x ≥ 0 and 0 otherwise. The clearance times for dead BTSCs and
progenitors after radiation are given by τs and τp, respectively. Further, αi for i ∈ {S, P}
represents the radiobiological parameters for BTSCs and progenitors. Experimental results
demonstrate that BTSCs are more resistant to radiation than CD133− cells (Bao et al.,
2006). Therefore, the radiosensitivity parameter for CD133− cells is chosen to be 3 fold
more than the radiosensitivity parameter for CD133+ cells (αs < αp).
The effect of BMPs is mathematically captured by reducing the probability r together
with fixing r2, which is the probability of BTSCs going through asymmetric self-renewal.
Following Piccirillo et al. (2006), it is assumed that r = r1 − r3 is changed from the
pretreatment value 0.1 to a negative value −0.1 after receiving BMPs. Modifying r to a
negative value implies an increase in symmetric differentiation divisions and a decrease in
symmetric self-renewing divisions. The effect of radiation kill is also examined for different
treatment schedules. Since the model assumes a higher radiosensitivity for CD133− cells,
the fraction of BTSCs is elevated. In addition, eradicating CD133− cells raises the number
of CD133+ due to the logistic growth impact on cell proliferation that necessitates a small
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increase in the number of BTSCs after radiotherapy (in comparison with the control group).
But, BMP therapy-only lowers the number of BTSCs at the expense of a slight increase
in the number of CD133− cells. Regardless, the results have shown that adding BMPs
or probably any other CSC targeting agents in addition to radiation therapy effectively
shrinks the tumor along with an associate decrease in CD133+ cells.
2.4 Finding the optimum treatment schedule under
the CSC hypothesis
Cancer treatments have evolved over time with the purpose of enhancing life expectancy
for cancer patients. In the last two decades, mathematical modeling has started to play
an important and pivotal role in developing optimal treatment strategies and protocols as
well as providing a new experimental tool for investigating the impact of a new proposed
therapy on tumor cells, in silico (Badri & Leder, 2016; Kohandel et al., 2006; Leder et
al., 2014; Powathil et al., 2007). For instance, the analysis and simulation of Powathil et
al. (2007) makes it clear that the combination of neo-adjuvent chemotherapy followed by
radiotherapy might be a better treatment strategy than adjuvant chemotherapy for gliomas.
Understanding the importance of targeting CSCs and their distinct properties may lead to
the development of new therapeutic protocols, which might achieve better tumor control.
As an example, Enderling et al. (2009b) presented a mathematical model that studies
the effect of CSCs and quiescent cells on treatment outcomes. The CSC fraction size
and the stem cell proliferation rates have been reported as critical factors determining
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treatment response. Assuming less radiosensitivity for quiescent cells, which are mainly
located in the core of a solid tumor, it has been suggested that applying hypofractionated
radiation protocols can control the disease if the CSC pool size is small and as long as the
CSC repopulation does not interfere with the higher capacity of radiation kill. Moreover,
heterogeneity and instability among various lineages of cancer cells can reduce the potency
of available treatment options. Hence, a mathematical model and an experimental study
were designed to predict an efficient radiotherapy regimen for Glioblastoma (Leder et al.,
2014). The model considers plasticity between CSCs and differentiated cells and assumes
that CSCs are more radioresistant. Furthermore, surviving cells lapse into a quiescent
state after radiotherapy, but can repopulate again, after exiting quiescence. Consequently,
two radiotherapy protocols, which deliver larger fractions at the beginning and end of
radiotherapy treatment, have been recommended claiming to lead to better outcomes than
conventional therapies. These predicted regimens have been tested experimentally and
demonstrated to lead to greater survival in mice. The model was later extended to predict
a radiotherapy regimen maximizing survival and minimizing toxicity in the corresponding
tissues arising from exposure to larger doses of radiation at the beginning and end of the
therapy (Badri et al., 2016). The problem is reduced to two optimization problems: the
first deals with optimization of the total dose and dose per fraction, and the second handles
optimization of time intervals for each fraction. The results obtained imply that the best
arrangement for the time intervals corresponds to the dose distribution that maximizes the
return to the stem like state. However, these approaches may lead to a growth in CSC
population, which can contribute to therapy resistance and recurrence.
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2.5 Conclusions
The emergence of resistance to conventional therapies has been long recognized as one of
the major causes of tumor relapse and recurrence. CSCs, also known as cancer initiating
cells, develop superior mechanisms such as activated DNA damage repair, upregulated
drug transporters, and maintenance of cellular pathways which allows them to survive
standard therapeutic protocols and triggers relapse in many cases. Therefore, identifying
and understanding the role of CSCs in therapeutic resistance can improve the overall
efficacy of available treatments and assist in the development of new treatment strategies
targeting CSCs. Here, mathematical modeling following experimental validation is useful
to understand the underlying mechanisms and design new treatment approaches.
Here, we have presented an idiosyncratic survey of mathematical models that inves-
tigate the impact of different characteristics of CSCs such as differentiation, quiescence,
and plasticity, on treatment response and emergent tumor resistance. However, CSCs em-
ploy other complex mechanisms such as upregulated drug transporters, which play critical
roles in the development of tumor resistance. Mathematical oncology is a nascent field of
research with the potential for significant clinical impact, but this requires much more the-
oretical investigation using mathematical and computational modeling validated through
experimental results. Moreover, studying the impact of microenvironmental effects ( e.g.
hypoxia) on the proliferation and control of CSCs may lead to significant advances in
clinical oncology.
Furthermore, in this chapter we have also reviewed mathematical models that provide
experimental predictions in the quest to develop new therapeutic strategies targeting CSCs.
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The main purpose of these new treatment strategies is to increase the sensitivity of CSCs
to chemotherapy and radiotherapy. This includes a combination of conventional therapies
with molecular inhibitors controlling CSC pathways, which enhance CSC death. Selfre-
newal is considered to be the main reason for radioresistance in CSCs, but understanding
other pathways such as those contributing to apoptosis is also of clinical interest (Ogawa et
al., 2013). Here, Mathematical modeling can be applied to predict other critical pathways
and possible clinical outcomes, which can be validated experimentally. In addition, using
chemotherapeutic agents together with radiotherapy to increase the effect of radiation on
CSCs have been shown to improve results. However, it is important that these agents
inflict minimal damage on normal stem cells since they share many of the same features
as CSCs (Eyler & Rich., 2008; Ogawa et al., 2013).
Current radiotherapy and chemotherapy schedules have been improved in an attempt
to optimize treatment outcomes and minimize toxicity. Mathematical models actively
play a crucial role in attempts to design better treatment strategies. Nevertheless, most
current clinical protocols still focus on reducing the tumor burden, and normally disregard
CSCs. This can lead to the emergence of resistant CSCs which in turn leads to relapse
and aggressive metastatic invasion. Thus, developing mathematical models suggesting
new therapeutic schedules that at the same time reduce the fraction of CSCs or include
recent molecularly targeted approaches can be helpful. Moreover, clinical and experimental
research to improve clinical outcomes are fields that have seen rapid growth in recent
years. For example Klement et al. (2000) suggested a combination therapy comprised of
continuous low dose chemotherapy regimen and a VEGF receptor-2 antibody, to increase
the antivascular effects of the treatment in order to shrink the tumor and reduce the
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evolution of drug resistance. Mathematical and computational approaches herald a new
era in clinical oncology with the potential to address questions arising from experimental
studies and vice-versa to guide experimental studies to resolve many of the puzzles and
paradoxes that are part and parcel of cancer biology. Indeed, we are optimistic that these
approaches will not only accelerate clinical developments, but elucidate and reveal some
of the basic mechanisms driving tumor growth.
(SS) is grateful for financial support provided by the Natural Science and Engineering
Research Council of Canada (NSERC) through a Discovery grant.
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Chapter 3
Mathematical modeling of the effects
of tumor heterogeneity on the
efficiency of radiation treatment
schedule
Radiation therapy uses high doses of ionizing radiation to eradicate cancer cells and con-
trol tumors. Various treatment schedules have been developed and tested in clinical trials,
yet there are still significant obstacles and there remains much room for improvement in
radiotherapy fractionation. Cellular diversity within tumors can lead to different radiosen-
sitivity among cancer cells that can affect radiation treatment outcomes. In this chapter,
we propose a minimal mathematical model to study the effects of tumor heterogeneity and
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repair under different radiation treatment schedules. We perform stochastic and deter-
ministic simulations to estimate model parameters using available experimental data. Our
results suggest that gross tumor volume reduction is not sufficient to control the disease if
a fraction of radioresistant cells survives therapy. If a cure cannot be achieved, protocols
should balance volume reduction with minimal selection for radioresistant cells. We show
that the most efficient treatment schedule is dependent on the biology and model param-
eter values and, therefore, emphasize the need for careful tumor-specific model calibration
before clinically actionable conclusions can be drawn. The model is also applied to the
fractionated radiotherapy protocols discussed in the UK standardisation of breast radio-
therapy (START) trials. The work reported here has been published in the peer reviewed
journal of Bulletin of Mathematical Biology:
Forouzannia, Farinaz, Heiko Enderling, and Mohammad Kohandel. Mathematical Mod-
eling of the Effects of Tumor Heterogeneity on the Efficiency of Radiation Treatment Sched-
ule. Bulletin of mathematical biology. 2017: 1-11. c©2017Springer.Reprintedwithpermission.
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3.1 Introduction
Radiation is a commonly used modality in cancer treatment, either as monotherapy or
as combination therapy together with surgery and/or chemotherapy. Radiation is a DNA
damaging agent; and radiation as cancer therapy is predicated on cancer cells being less
efficient in repairing radiation-induced damage than normal cells. The total radiation dose
is divided into small fractions and administered in a regular periodic fashion to provide
temporal windows for normal tissue recovery. Treatment schedules (fractionation) are
predominantly based on evolving empirical knowledge and wisdom, but greatly constrained
by logistical considerations. Recent developments include hypo- and hyperfractionation for
various cancer types, that is delivery of either larger doses temporally further separated or
smaller doses more frequently.
Despite many technical improvements in the efficiency of radiotherapy, many tumors
become refractory to irradiation. Various clinical and biological factors explain such com-
plications, including DNA damage repair (Hall & Giaccia, 2006; Mathews et al., 2013),
prevalence of hypoxia, and tumor heterogeneity and plasticity. Recently, the presence of
cancer stem cells and a tumor hierarchy has been discussed as a source of intratumoral het-
erogeneity and poor therapy response (Marjanovic et al., 2013a; Shackleton et al., 2009).
The cancer stem cell hypothesis proposes that a small sub-population of so-called cancer
stem cells (CSCs) is critically important for the initiation and maintenance of a tumor.
These CSCs are able to self-renew indefinitely, and undergo symmetric and asymmetric
divisions to retrospectively increase the CSC population and produce progenitor cells that
will make up the bulk of the tumor (Reya et al., 2001). Recent evidence suggests plasticity
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between non-CSC and CSC states (Gupta et al., 2011), due to genetic or microenviron-
mental perturbations. CSCs have been shown to utilize superior radiation-induced DNA
damage repair mechanisms to prevent cell death (Bao et al., 2006). After radiation expo-
sure, cells with damaged DNA attempt different pathways of repair, and the repair time is
likely dependent on the delivered radiation dose (Lagadec et al., 2010; Sarcar et al., 2011).
The conventional radiotherapy protocol for most tumors delivers a total dose of 50−70
Gy in 2 Gy fractions on each weekday, with no treatment given on weekends. To reduce
toxicity and increase efficacy, alternative treatments have been considered, including a
hyper-fractionated protocol with 1 Gy per fraction twice a day; an accelerated regimen of
1.2 Gy per fraction twice daily; and hypo-fractionation with 5 Gy twice-a-week fractions.
Here, we develop a minimal mathematical model to study the effect of tumor heterogeneity
and repair in tumors exposed to theses different radiation treatment schedules.
Several mathematical models have been developed to simulate the effects of radio-
therapy. Most models utilize the so-called linear quadratic (LQ) model and its various
extensions (Hall & Giaccia, 2006). In the original LQ model, cell survival probability S
after acute doses of radiation d can be estimated as
S(d) = exp(−αd− βd2), (3.1)
where α (Gy−1) and β (Gy−2) are tissue-specific radiosensitivity parameters that are usu-
ally derived from fitting the LQ model to clonogenic survival data (Hall & Giaccia, 2006).
More recently, mathematical frameworks have been combined with experimental data to
investigate the different responses to clinically available radiation protocols (Dhawan et al.,
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2014; Dionysiou et al., 2004; Enderling et al., 2009b; Stamatakos et al., 2006). Recently,
Leder et al. (2014) proposed an optimized radiation dosing schedule for PDGF-driven
glioblastoma. The model, however, is dependent on a large number of parameters and,
with limited biological data, some parameters are far from biological realism. In partic-
ular, tissue-specific radiosenstivity parameters α and β are derived such that the derived
ratio of α/β = 865, 789 Gy is five orders of magnitude larger than frequently derived
α/β = 3 − 10 Gy (Leder et al., 2014). Nevertheless, the model-predicted optimal dose
fractionation showed prolonged survival in subsequent mouse experiments, emphasizing
that the currently applied standard-of-care radiation fractionation may not yield optimal
outcomes. Mathematical models may help decipher the complex biology underlying cancer
cell response to irradiation, with the ultimate aim of improving clinical applications of
radiotherapy.
Herein we propose a simple mathematical model of breast cancer cell dynamics under
fractionated radiation exposure. The model includes phenotypic cell heterogeneity and
plasticity, as well as radiation-induced cell cycle arrest, which may play a pivotal role in
analyzing radiation protocols with multiple doses per day. The effect of different model
parameters and repair mechanisms on heterogeneity are studied for different clinically
feasible radiotherapy treatments. Finally, the model is applied to fractionated radiation
protocols obtained from UK standardization of breast radiotherapy (START) trials. The
START trials (START A and START B) were two experiments applied randomly to a
group of women who received radiation as part of their treatment for breast cancer in the
UK between 1999 and 2002 (Haviland et al., 2013).
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3.2 Method
We developed a two-compartment mathematical model to analyze the effect of radiation
therapy on the two phenotypically distinct sub-populations of radioresistant and radiosen-
sitive cancer cells. In breast cancer, these populations have been identified by respectively
CD44highCD24low (CD+; biomarker positive) and CD44lowCD24high (CD−; biomarker
negative), which are also markers of cancer stemness (Al-Hajj et al., 2003; Fillmore &
Kuperwasser., 2008). Both sub-populations are capable of self-renewal, albeit with lower
rates for biomarker negative CD− cells that also feature higher death rates. We discuss
the balance of self renewal and cell death as the net population growth rate, which does
not affect the behavior of the system. As a visualization of phenotypic plasticity, cells
can switch from one phenotype to the other (Marjanovic et al., 2013a). After exposure
to radiation, cells in each compartment are forced into cell cycle arrest to attempt repair
from radiation-induced DNA damage. Biomarker positive cells have been shown to have
better repair mechanisms (Bao et al., 2006; Boman et al., 2008) and, thus, a larger fraction
of growth-arrested biomarker positive CD+ (calculated by the LQ model with phenotype-
specific αS and βS parameters) returns into the viable population after successful repair.
Figure 3.1 shows a schematic diagram of the proposed model, and model parameters are
summarized in Table 3.1.
We denote by NS, NRS, NP and NRP the population of resistant cells, resistant re-
pairing cells, sensitive cells, and sensitive repairing cells, respectively. The model can be















CD44high/CD24low (CD+) Repairing cells (CD+)  
Negative biomarker cells
CD44low/CD24high (CD-)
Repairing cells (CD-)  
Dead cells (CD+)  
Dead cells (CD-)  
Figure 3.1: Schematic diagram of the model.
dNS
dt
= ρSNS + ρPSNP + g(d)e
(−αSd−βSd2)NRS − ρSPNS − δSfNS,
dNRS
dt
= δSfNS − g(d)NRS,
dNP
dt
= ρPNP + ρSPNS + g(d)e
(−αP d−βP d2)NRP − ρPSNP − δPfNP ,
dNRP
dt
= δPfNP − g(d)NRP .
(3.2)
Cells acquire on average one DNA double strand break after exposure to 1 Gy of radiation.
Therefore we assume that each cell will enter cell cycle arrest and attempt repair after each
radiation fraction, but no new damage arises in the interval between radiation treatments.
Hence, f = 1 at discrete times when radiation is given, and f = 0 otherwise. Dependent on
radiosensitivity parameters αi and βi with i ∈ {S, P}, cells will either die due to radiation
induced DNA damage with probability 1 − Si(d) or return to the viable non-repairing
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Table 3.1: Description of the model parameters.
Parameters Description
ρS Net proliferation rate of CD
+ cells.
ρSP Rate of switching of CD
+ cells to CD− cells.
ρP Net proliferation rate of CD
− cells.
ρPS Rate of switching of CD
− cells to CD+ cells.
δSf Rate at which CD
+ cells go for repair.
δPf Rate at which CD
− cells go for repair.
g(d)(1− e(−αSd−βSd2)) Rate at which CD+ cells that are in repair die.
g(d)(1− e(−αP d−βP d2)) Rate at which CD− cells that are in repair die.
g(d)e(−αSd−βSd
2) Rate at which CD+ cells that are in repair become active again.
g(d)e(−αP d−βP d
2) Rate at which CD− cells that are in repair become active again.
population S or P with probability Si(d) at dose-dependent rate g(d). We assume the
function g(d) to be of the order of the inverse square of the dose (Lagadec et al., 2010;
Sarcar et al., 2011), such that cells irradiated with a dose of 1 Gy spend on average 1 hour
attempting repair, and 4 hours after exposure to 2 Gy.
3.2.1 Parameter estimation
Stochastic and deterministic simulations have been compared to two sets of experimental
data to derive suitable values for model parameters. The experimental study on breast
cancer initiating cells (i.e. CSCs) and mammosphere formation assay (MFA) data cali-
brates the fraction of biomarker positive CSCs (Lagadec et al., 2010). In this study, the
breast cancer cell line is irradiated with a single dose or daily doses of 2 Gy. After 48 hours,
single cells are seeded to form spheres for 20 days. The fraction of CSCs and mammosphere
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formation capacity are reported in Table 3.2 (Lagadec et al., 2010).
Table 3.2: The fractionated irradition effect on CSC population and mammosphere forma-
tion capacity (Lagadec et al., 2010).
CD24low/−/CD44high
Dose % of CSCs Sphere forming capacity
2 6.54 (+/- 1.95) 13.49 (+/- 1.32)
2-2 8.04 (+/- 1.47) 10.76 (+/- 0.96)
2-2-2-2 8.56 (+/- 1.21) 11.85 (+/- 1.81)
Overall average 7.71 12.03
As the MFA experiment was initiated from a single cell (Lagadec et al., 2010), stochastic
effects are important. We apply the Gillespie algorithm to compare model sphere forming
capacity predictions with the experimental data in Table 3.2. Since running the Gillespie
algorithm is computationally expensive, it is only used to fit the parameters of the model
when δs = δp = g = 0. We vary model parameters without repair to obtain the best fit to
the experimental data. At the same time, we use the deterministic equations 3.2 to compare
the theoretical results of average CSC fraction to experimental data. The estimated model
parameters are summarized in Table 3.3, alongside the fraction of CSCs and sphere forming
capacity using those values, which show good agreement with the experimental results in
Table 3.2. Of note is that the reported parameter value combinations are not unique and,
thus, we will perform a sensitivity analysis to investigate the impact of each parameter on
model outcome.
Herein, resistant and sensitive tumor cells are considered to have different radio-sensitivities.
Thus, the total population of cells at time t is given by N(t) = NS(t) +NP (t) (Hereafter,
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Table 3.3: Estimated model parameters when δS = δP = g = 0. The values of fraction of
CSCs and sphere forming capacity that are evaluated based on the estimated parameters
values are also reported. The unit of all parameters is 1/day.
Parameters ρS ρSP ρP ρPS % of CSCs Sphere forming capacity
Values 0.2 0.7 0.1 0.05 7.6 12.7
NS ≡ NS + NRS and NP ≡ NP + NRP unless stated otherwise); the population of cells












Assuming that the fraction of CSCs is at its steady state value before the radiation, and
using the experimental data of (Lagadec et al., 2010), we set NS(t)
N(t)
= 0.076 (and NP (t)
N(t)
=
0.924). Then, the modified linear quadratic model (Equation 3.3) is used to fit model
results to the experimental data of (Piccirillo et al., 2006), which yields αS = 0.14 Gy
−1,
βS = 0.048 Gy
−2 (αS/βS=2.9 Gy), αP = 0.41 Gy
−1 and βP = 0.17 Gy
−2 (αS/βS=2.4
Gy) (Figure 3.2). Since at each radiation fraction the majority of damaged cells undergo
repair mechanisms, we assume that 90% of cells will be arrested (Withers, 1992). However,
sensitivity analysis shows that reducing this fraction to as low as 40% does not qualitatively
change the results (see Figure A.1 and Figure A.6 in supplementary materials). The list
of all model parameters and their estimated values are reported in Table 3.4.
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Figure 3.2: Fitting the modified linear quadratic model to the experimental data of (Pic-
cirillo et al., 2006). The black points are the extracted experimental data. The solid
curve is the model result using the estimated radio-sensitivity parameters αS = 0.14 Gy
−1,
βS = 0.048 Gy
−2, αP = 0.41 Gy
−1 and βP = 0.17 Gy
−2.
3.3 Results
We consider different clinical radiotherapy treatment protocols for one week including stan-
dard of care (SoC; daily doses of 2 Gy), hyperfractionated (HR; two daily doses of 1 Gy),
accelerated hyperfractionation (AC; two daily doses of 1.2 Gy), and hypofractionated (HO;
twice a week doses of 5 Gy). Additionally we simulate the recently suggested optimal pro-
tocol for PDGF-driven glioblastoma by Leder (Leder et al., 2014) (Optimum-1, OP; see
Table 3.5). All protocols deliver a total dose of D = 10 Gy per week, except accelerated
hyperfractionated with a total dose of D = 12 Gy. However, the accelerated hyperfrac-
tionated protocol has the same biologically effective dose (BED) as SoC (see Table 3.6).
BED is used to describe the biological effect of dose fractionation, and is defined as
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Table 3.4: Model parameter values.
Parameters Value (unit) Reference
ρS 0.2 (day
−1) Using experimental data (Lagadec et al., 2010)
ρSP 0.7 (day
−1) Using experimental data (Lagadec et al., 2010)
ρP 0.1 (day
−1) Using experimental data (Lagadec et al., 2010)
ρPS 0.05 (day
−1) Using experimental data (Lagadec et al., 2010)
δS = δP 310 (day
−1) Assuming 90% of cancer cells undergo repair
αS 0.14 (Gy
−1) Using experimental data (Piccirillo et al., 2006)
αP 0.41 (Gy
−1) Using experimental data(Piccirillo et al., 2006)
βS 0.048 (Gy
−2) Using experimental data (Piccirillo et al., 2006)
βP 0.17 (Gy
−2) Using experimental data (Piccirillo et al., 2006)








where SF (d) is the LQ Model derived single dose d dependent survival fraction with
radiobiological parameters α and β (compare Equation 3.1). Due to the linear quadratic
relationship of dose and survival, total dose can be increased when smaller doses are given in
each fraction (Fowler, 1989). The model introduced in Section 3.2 considered two subgroups
of cancer cells (resistant cells and sensitive cells) with different radiosensitivities. Thus,
following the survival fraction of cancer cells in equation 3.3, the BED is given by
BED =
− ln(mSFS + (1−m)SFP )
mαS + (1−m)αP
, (3.5)
where SFS and SFP are survival fractions for resistant cells and sensitive cells respectively.
The constant m represents the proportion of resistant cells in the tumor prior to irradiation.
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Table 3.6 shows the BED for the standard of care (SoC), hyperfractionated (HR), and
accelerated hyperfractionated (AC) protocols with different initial fractions of resistant
cells: Tumors containing only resistant cells (m = 1), tumors containing only sensitive
cells (m = 0), and heterogeneous tumors with a small subpopulation of resistant cells
(m = 0.076) as estimated. The BED is almost identical for standard of care and accelerated
hyperfractionation, but significantly smaller for hyperfractionation.
Table 3.5: Radiotherapy schedules for one week of treatment. Different colors are used for
corresponding colors in the figures.
Schedule Day 1 Day 2 Day 3 Day 4 Day 5
Standard of Care (SoC) 2 2 2 2 2
Hyperfractionated (HR) 2×1 2×1 2×1 2×1 2×1
Optimum-1 (OP) 3×1 1 2×1 1 3×1
Hypofractionated (HO) 5 - - - 5
Accelerated hyperfractionated (AC) 2×1.2 2×1.2 2×1.2 2×1.2 2×1.2
Table 3.6: The Biological effective dose for Hyperfractionation, Standard of Care, and
Accelerated Hyperfractionated protocols.
Schedules
BED HR (d=1, n=10) SoC (d=2, n=5) AC (d=1.2 n=10)
BEDS (m=1) 13.5 17.1 17.1
BEDP (m=0) 14.1 18.3 17.9
BEDSP (m=0.076) 11.1 12.7 12.7
Figure 3.3 shows the number of cancer cells NS + NP and fraction of resistant cells
NS/(NS + NP ) for all considered radiation schedules (compare Table 3.5). Simulations
44
show that protocols with larger number of fractions leads to more cell kill, with acceler-
ated hyperfractionation yielding the smallest number of cells after one week of therapy.
However, the fraction of stem cells is largest compared to the other radiotherapy protocols.
Hypofractionation with smallest overall cell kill leads also to least competitive release of
the most resistant stem cell subpopulation (Enderling et al., 2009a).














































Approximately 90% of cells go for repair
Figure 3.3: The number of cancer cells NS+NP and the fraction of resistant cells NS/(NS+
NP ) for radiotherapy protocols reported in Table 3.5.
For the chosen parameter combinations (Table 3.4), accelerated hyperfractionation and
SoC schedules yield the lowest number of cancer cells after one week of treatment (Figure
3.3). Sensitivity analysis showed that the results are robust to changes in the parame-
ter values (Table 3.7), with the exception that decreasing αP and βP by 50% produces
hypofractionated and accelerated hyperfractionated as best protocols (Figure 3.4).
Heretofore we assumed that 90% of cells undergo arrest to attempt repair, and the pa-
rameter values for δS and δP were chosen large enough to satisfy this assumption. However,
decreasing the values for these parameters so that less than 40% of cells attempt repair
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suggests accelerated hyperfractionated as the best schedule (see Figure A.1 and Figure A.6
in Appendix A). Furthermore, the model considers that cells leave arrest with rate g(d),
which is assumed to be on the order of 1/dose2. If g(d) was proportional to 1/dose the
number of cancer cells at the end of the course of radiation therapy decreases significantly;
however, the accelerated hyperfractionated schedule remains the best treatment protocol
followed by SoC. Moreover, if g(d) = 1, the order of the best treatment regimens remains
(see Figure A.3, Figure A.4, and Figure A.5 in Appendix A).
Table 3.7: Sensitivity analysis for different parameters of the model.
Parameters αS, βS αP , βP ρS ρP ρPS ρSP 1
st best 2st best
Default 0.14, 0.05 0.41, 0.17 0.2 0.1 0.044 0.73 AC SoC
αS, βS (+50%) 0.21, 0.07 0.41, 0.17 0.2 0.1 0.044 0.73 AC SoC
αS, βS (-50%) 0.07, 0.04 0.41, 0.17 0.2 0.1 0.044 0.73 AC SoC
αP , βP (+50%) 0.14, 0.05 0.61, 0.25 0.2 0.1 0.044 0.73 AC SoC
αP , βP (-50%) 0.14, 0.05 0.21, 0.08 0.2 0.1 0.044 0.73 HO AC
ρS (+50%) 0.14, 0.05 0.41, 0.17 0.3 0.1 0.044 0.73 AC SoC
ρS (-50%) 0.14, 0.05 0.41, 0.17 0.1 0.1 0.044 0.73 AC SoC
ρP (+50%) 0.14, 0.05 0.41, 0.17 0.2 0.15 0.044 0.73 AC SoC
ρP (-50%) 0.14, 0.05 0.41, 0.17 0.2 0.05 0.044 0.73 AC SoC
ρPS (+50%) 0.14, 0.05 0.41, 0.17 0.2 0.1 0.066 0.73 AC SoC
ρPS (-50%) 0.14, 0.05 0.41, 0.17 0.2 0.1 0.022 0.73 AC SoC
ρSP (+50%) 0.14, 0.05 0.41, 0.17 0.2 0.1 0.044 1.09 AC SoC
ρSP (-50%) 0.14, 0.05 0.41, 0.17 0.2 0.1 0.044 0.36 AC SoC
The UK standardisation of breast radiotherapy (START) trials constituted a study con-
ducted to reduce late normal tissue complications and local tumour control in women with
breast cancer exposed to radiotherapy after tumor removal (The START Trialists’ Group,
2008). The study consisted of two parallel trials, START A and START B, which con-
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Approximately 90% of cells go for repair
Figure 3.4: The number of cancer cells NS+NP and the fraction of resistant cells NS/(NS+
NP ) when αP and βP are changed to αP −0.5αP and βP −0.5βP for radiotherapy protocols
reported in Table 3.7 .
sidered the standard radiotherapy protocol, including 50 Gy in 25 fractions delivered in 5
weeks, one highly-prescribed protocol. To reduce tumour relapse and normal tissue dam-
age, the schedule was improved based on normal and cancerous cells radiosensitivities and
their response to fractionated doses. Therefore, the conventional protocol was modified to
deliver higher amounts of radiation at each fraction with acceptable reduction in the total
dose. In the START A trial, patients were arbitrarily exposed to five weeks of treatment
with either 50 Gy in 25 fractions, 41.6 Gy in 13 fractions, or 39 Gy in 13 fractions. In the
START B study, patients were randomly assigned to either 50 Gy in 25 fractions over 5
weeks or 40 Gy in 15 fractions for three weeks (Haviland et al., 2013). The model proposed
in this current chapter uses the treatment schedules discussed in the START trials to ex-
plore tumour diversity after each course of radiation. In addition, sensitivity analysis has
been carried out to explore the effects of model parameters on the radiotherapy schedules
used in the START trials.
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The number of cancer cells and fraction of resistant cells for the treatment protocols
reported in the START trails are presented in Figure 3.5. The conventional regimen
treatment with total dose 50 Gy has the smallest number of cancer cells and a relatively
high fraction of resistant cells. Thus, this Conventional treatment schedule can be effective
to kill cancer cells, but the probability of relapse is fairly high. In addition, the treatment
schedule with total dose 40 Gy, represents the highest number of cancer cells and highest
fraction of resistant cells, which imply that this hypofractionated regimen is not efficient
in curing the disease and it can also cause late side effects and relapse. On the contrary,
the study conducted in the START trials reports that hypofractioned schedules are as
safe and effective as standard control protocols. The sensitivity of the results to the
parameters of the model was investigated. The outcome concluded that αP and βP were
the most important parameters. The number of cancer cells and fraction of resistant cells
when αP and βP are changed to αP − 0.5αP and βP − 0.5βP are sketched in Figure 3.6.
As seen, the hypofractionated regimen with total dose 41.6 Gy behaves similarly to the
standard control schedule with a lower fraction of resistant cells. Thus, the impact of
the radiotherapy with respect to the treatment for these two protocols are comparable,
however the hypofractionated schedule results in a smaller probability of relapse.
As previously stated, due to the fatal effects of 1 Gy of radiation, δS and δP are selected
adequately large such that 90% of cells undergo DNA repair pathways. The reduction in the
values of these parameters, so that less than 40% of cells go through repair stage, can change
the behavior of the hypofractionated regimen (with total dose of 40 Gy) significantly. This
hypofractionated protocol is improved to the second order in terms of the number of cancer
cells. Furthermore, the fraction of resistant cells is comparatively similar to the fraction
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Clinical trials schedules (90% of cells go for repair)











Clinical trials schedules (90% of cells go for repair)
Figure 3.5: The number of cancer cells NS+NP and the fraction of resistant cells NS/(NS+
NP ) for the radiotherapy schedules reported in START trials.
of resistant cells for the Control conventional treatment strategy, but still worse than the
other hypofractionated schedules. Thus, the hypofractioned protocol with total dose 40
Gy is at least as efficient as the conventional regimen (see Figure A.6 in Appendix A). The
sensitivity of the outcomes to the assumption of the function g(d) is also studied. Two
sets of assumptions have been considered for the function g(d) in this study: the inverse of
the dose delivered at each fraction of treatment and the constant value 1. For the former
assumption, the number of cancer cells decreases and the order of the schedules has not
been changed. For the latter, the number of cancer cells also decreases and the treatment
protocols show no qualitative differences (see Figure A.7 and Figure A.8 in Appendix A).
Furthermore, the hypofractionated schedule (with a total dose of 40 Gy) drops quickly in
comparison with the other three regimens when the function g(d) is changed from being
proportional to the inverse square of dose to the inverse of dose (see Figure A.9 in Appendix
A).
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Clinical trials schedules (90% of cells go for repair)
Days
Clinical trials schedules (90% of cells go for repair)
Figure 3.6: The number of cancer cells NS+NP and the fraction of resistant cells NS/(NS+
NP ) for the radiotherapy schedules reported in START trials when αP and βP are changed
to αP − 0.5αP and βP − 0.5βP .
3.4 Conclusion
In this chapter, a two-compartment mathematical model has been developed to assess
the effects of tumor heterogeneity and radiotherapy fractionation on treatment response.
Model simulations suggest that radiotherapy can alter tumor heterogeneity, and elevate
the fraction of resistant cells. In future studies, we propose to further increase biological
complexity by considering increased self-renewal of the resistant population in response
to radiation (Gao et al., 2013). If the total radiation dose is insufficient to eradicate the
tumor, enrichment in cancer stem cells may lead to tumor relapse and recurrence. There-
fore, if total tumor control cannot be achieved, optimal therapies should balance decreases
in tumor burden and prevention of outgrowth of the most resistant subpopulation. Inter-
estingly, none of our simulations suggested the standard of care fractionation as the best
therapeutic approach, further emphasizing the need to prospectively evaluate alternative
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fractionation protocols in the clinic. Furthermore, our model calibrated for breast cancer
was unable to confirm the optimum treatment schedule for PDGF-driven glioblastoma (as
in Leder et al., 2014). This suggests that treatment optimization may be highly dependent
on the tumor biology, the mathematical model, and model parameter dependent, and the
utmost attention must be paid to identifying the underlying biological mechanisms. Hence,
a general optimal radiation schedule as suggested in (Conforti et al., 2008; Leder et al.,
2014; Wein et al., 2000) may not be feasible, and designing different efficient protocols may
be required for each type of cancer, and even each individual patient.
The model has also been applied to the START trials to investigate the effect of the
proposed protocols on tumor heterogeneity. In START trials, radiotherapy is administered
after surgery and chemotherapy. Many different features such as demographic factors, and
the stage and type of the disease can influence the results. Thus, our aim in this chapter was
not to compare the model predictions with START trials outcomes, but rather to consider
the impact of the radiotherapy schedules on tumor diversity. In general, the results suggest
that the number of cells is minimal after the standard regimen, but the fraction of resistant
cells is relatively high. In addition, the other three hypofractionated protocols, with larger
doses of fractions and lower total dose, have different effects on cancer cell dynamics. For
example, both the number of cancer cells and the fraction of resistant cells are large after
exposure to the schedule with a total dose of 40 Gy. The regimens with total doses of 41.6
Gy and 39 Gy reduce the fraction of resistant cells to the minimum in comparison with
other schedules, but the number of cells is still bigger than that after standard schedules.
At the moment, the study is hypothesis generating, and we sincerely hope that the pre-
sented results stimulate and encourage experimentalists and clinicians to test the presented
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model predictions.
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Chapter 4
The impact of random
microenvironmental fluctuations on
tumor control probability
The tumor control probability (TCP) is a metric used to calculate the probability of con-
trolling or eradicating tumors through radiotherapy. Cancer cells vary in their response
to radiation, and although many factors are involved, the tumor microenvironment is a
crucial one that determines radiation efficacy. The tumor microenvironment plays a signif-
icant role in cancer initiation and propagation, as well as in treatment outcome. We have
developed stochastic formulations to study the impact of arbitrary microenvironmental
fluctuations on TCP. Since the derivation of analytical solutions may not be possible for
complicated cases, we employ a modified Gillespie algorithm to analyze TCP, and take into
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consideration the random variations in cellular proliferation and death rates. Our results
show that increasing the standard deviation in demographic factors initially enhances the
probability of tumor eradication. However, if the TCP does not reach a probability of 1,
the increase in the standard deviation subsequently has a negative impact on treatment
effectiveness, decreasing the TCP over time. The greatest effect on TCP has been observed
when both birth and death rates are being randomly modified and are anticorrelated.
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4.1 Introduction
Radiotherapy delivers high doses of energy to disrupt cancer cell proliferation and destroy
tumor cells with the ultimate goal of maximizing tumor control and minimizing normal
tissue complication. Radiotherapy efficiency and tumor response depend on many different
factors, such as the degree of tumor heterogeneity, plasticity, hypoxia, the tumor microen-
vironment, and cell cycle regulation. The tumor microenvironment, which also creates
substantial barriers to the delivery and effectiveness of anticancer treatments, consists of
different cellular types such as vascular networks, immune system cells, fibroblasts, and
inflammatory cells. The complex interaction between the tumor microenvironment and
a heterogenous cancer cell population influences tumorigenesis, metastasis, and therapeu-
tic outcomes. For example, the irregular signaling pathways regulating malignant cells
simulate the activation of fibroblasts and other molecular mechanisms that impact cell
proliferation (Wang et al., 2017). Moreover, the active process of angiogenesis generates
abnormal vascular structures, which increase leakiness and elevate interstitial fluid pres-
sure in the tumor, and interrupting the regular blood flow in the tissue (Fukumura & Jain,
2007; Hanahan & Weinberg, 2011). Consequently, these random and complicated inter-
actions create regions of hypoxia and acidosis, leading to more aggressive and resistant
tumor cells that prevent effective therapeutic interventions. The impact of such irregular
fluctuations in natural selection and the fitness of emerging mutants have been discussed
for a heterogenous population (Mahdipour et al., 2017; Nowak et al., 2003), but the effect
of random environmental variations on tumor response to therapeutic protocols is not yet
well understood.
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The efficiency of radiotherapy and potential benefits of various treatment schedules
are commonly evaluated using a range of treatment-planning tools and approaches. For
example, the tumor control probability (TCP) qualitatively calculates the capability of
administered doses and radiotherapy regimens to eliminate a tumor. Several mathematical
models of TCP have been discussed in the literature (Kendal, 1998; Munro & Gilbert, 1961;
Tucker et al., 1990; Yakovlev, 1993; Zaider & Minerbo, 2000). One of the preliminary
models proposed that the probability of eradicating cancer cells approximates a Poisson
distribution, if the number of surviving cells follows a binomial distribution (Zaider &
Minerbo, 2000). However, the Poisson model of TCP does not consider cell proliferation
during treatment and might underestimate the exact TCP (Tucker et al., 1990; Yakovlev,
1993). Zaider & Minerbo (2000) developed another well known TCP model to incorporate
stochastic effects on cell proliferation and cell kill. This model was suggested based on a
simple birth/death process and can be applied to any treatment protocol. The extension of
these models and other approaches such as Monte Carlo simulations have been employed
to take cell cycles and quiescent effects into consideration (Dawson & Hillen, 2006; Gong,
2011).
In this chapter, a stochastic model is developed to investigate the role of tumor mi-
croenvironmental fluctuations on tumor control probability. The arbitrary fluctuations in
cell birth and death rates are modelled using a dichotomous Markov noise, which describes
either birth and/or death rates as correlated noise with random discontinuous jumps. The
derivation of the analytical solution is complicated when demographic rates change ran-
domly. Therefore, a modified Gillespie algorithm for time changing discontinuous transition
rates is applied to study the TCP. The results suggest that if either birth or death rates
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change randomly, the probability of tumor eradication initially improves, however, random
changes negatively impact TCP over time. Moreover, changing both birth and death rates
such that cells with higher proliferation rates die with lower death rates has the highest
impact on TCP. In this case, TCP is improved if birth and death rates are autocorrelated,
and the best outcome is when cells with higher birth rates die with higher death rates.
4.2 Method
We assume that cancer cells can reproduce by splitting into two at a rate of ρ(t) and can
die autonomously at a rate of Γ(t). In order to determine the stochastic dynamic of the
model, we first define the probability distribution function for the system. Suppose that at
an initial time, t0, the number of cancer cells is denoted by n0. The probability distribution




= ρ(t)pnc−1(nc − 1)− (ρ(t) + Γ(t))pncnc + Γ(t)pnc+1(nc + 1), (4.1)
where ρ(t) and Γ(t) are the corresponding birth rate and death rate for cancer cells, respec-
tively. Here, the initial condition is given by pnc(t0) = δncn0 (with δi,j being the Kronecker















with initial condition U(z, 0) = zn0 .
Partial differential equation 4.2 can be solved using the method of characteristics. Let














Assuming that U(z(τ), t(τ)) is constant along this characteristic curve, we get dU
dτ
= 0.
Comparing 4.2 and 4.3 results in
dz
dτ
= −(z − 1)(ρ(τ)z − Γ(τ)), (4.4)
relabelling τ as t gives
dz
dt
= −(z − 1)(ρ(t)z − Γ(t)), (4.5)
which can be written as
dz
dt
= −(z − 1)(β(t)− (1− z)ρ(t)), (4.6)
























a constant, and since U(z, t) is constant along the characteristic curve, we get
U(z, t) = f
(
(1− z)
λ(t) + (1− z)φ(t)
)
. (4.8)











and TCP can be defined as the probability of eradicating all cancer cells, given as below









Evaluating equation 4.10 is trivial for the simple functional forms of ρ(t) and λ(t). However,
the analytical computation can be difficult for more complicated functions ρ(t) and λ(t).
In this latter case, numerical methods are beneficial. One possible approach is to solve
differential equation 4.5 numerically (Appendix B). Alternatively, the master equation,
4.1, can be solved using the Gillespie algorithm. These three approaches are compared
below to show that the Gillespie algorithm is a suitable method when the rates are either
constant or vary over time (for simplicity we assume that ρ(t) is constant). Reducing
a partial differential equation to a related ordinary differential equation and deriving the
analytical solution may not always be possible. However, the Gillespie algorithm is a useful
approach for solving complicated systems.
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Constant Γ(t)
Here, the mortality rate is assumed to be uniform over time (i.e. Γ(t) is constant). The
results show that there is good agreement among the analytical solution, the numerical
method, and the Gillespie algorithm, assuming death rates are constant (Figure 4.1).
Figure 4.1: Comparison of the analytical solution, the numerical method, and the Gillespie
algorithm, when n0 = 100, ρ = 0.5 and Γ = 1.
Γ(t) changes over time
In practice, it is not realistic to assume that the death rate is constant over time. For
instance, when fractionated radiotherapy is given, the total administered dose is broken
down into smaller fractions of doses, decreasing toxicity and damage to normal cells as
well as increasing efficiency. Therefore, based on the prescribed protocol, each fraction is
given for 15-30 minutes once or twice a day. The cell kill effect can be described as a step
function in which there is a higher cell death rate in the presence of radiotherapy and a
lower death rate when there is no radiation. Hence, Γ(t) is assumed to be a piecewise
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function given as below when k1 > k2.
Γ(t) =

k1 radiation induced cell death,
k2 radiation independent cell death.
(4.11)
As described above, for an analytical solution, ρ(t) and Γ(t) must be continuous functions.






)) to smooth out the approximation to the discontinuous Heaviside
function H(x), where δ determines the width of the smooth transition. Figure 4.2 compares
the analytical, numerical, and Gillespie solutions for the two different cell-kill functions.
The last uses a modified Gillespie algorithm for rates that change discontinuously over
time (see Appendix C). The results show good agreement between the analytical solution
and the Gillespie algorithm. However, the numerical solution displays an error, which
is probably due to the instability of finite difference methods in the presence of sharp
changes. Although, the error is negligible for linear differential equations, it can be large for
nonlinear ones. Using the numerical method given in Appendix (B), TCP(t) equals the n0-
th power of the solution for the differential equation 4.5, and the relative error for TCP(t)
approximately equals n0δz, where δz is a relative error in z. Resolving this issue is not
within the scope of this work, which focuses on applying the modified Gillespie algorithm




Figure 4.2: Comparison of the analytical solution, the numerical method, and the Gillespie
algorithm, when n0 = 100 and ρ = 0.5, for two different cell kill rates: (a) Γ = 0.4 for
6 < t ≤ 10 and Γ = 1 otherwise. (b) Γ = 8 (every day for 3 hours) and Γ = 1 otherwise.
The role of arbitrary fluctuations on TCP
Cancer cells live in a complex and ever-changing microenvironment that has a performed
impact on their behavior and fate. For example, inflammation, hypoxia, and acidosis in
and around a tumor can contribute to treatment resistance, reducing treatment induced
cell kill effects. In this direction, we investigate TCP for a cancer cell population that
is subject to microenvironmental randomness. Therefore, the simple birth/ death model
discussed above is considered. To incorporate microenvironmental-induced fluctuations in
the model, the proliferation and death rates are assumed to exchange stochastically between
two values, k1 and k2, with an average k = (k1 + k2)/2. This stochastic fluctuation occurs
continuously based on dichotomous Markov noise ξ(t) ∈ {−1,+1} with zero mean and
autocorrelation 〈ξ(t)ξ(t′)〉 = exp(−2ν|t − t′|), where ν is the rate of random changes and
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1/(2ν) is the finite correlation time. Thus, proliferation and death rates are given by
1
2
[ (k1 + k2) + ξ(t)(k1 − k2)] . (4.12)
The addition of this noise to the system describes birth and death rates as random step
functions, changing over time. Consequently, we calculate TCP using a modified Gillespie
algorithm for different switching rates, ν.
4.3 Results
4.3.1 Random birth rate
In this section, we consider Γ(t) = Γ to be constant, and ρ(t) = 1
2
[ (k1 +k2)+ξ(t)(k1−k2)],
which alters stochastically, following the dichotomous Markov noise explained above. Here,
TCP is measured for different random change rates ν. In addition, it is assumed that ρ(t)
alters randomly over time between two values k1 and k2 that are equidistant from the
average (k). Thus, k1 = k + σ and k2 = k − σ, where σ is a standard deviation. The
results show that tumor control probability approaches TCP, corresponding to a constant
proliferation rate, as the random change rate (ν) increases or the finite correlation time
(1/(2ν)) decreases ( Figure 4.3 ). Furthermore, as Figure 4.4 demonstrates, as the standard
deviation (σ) increases, the probability of eradicating cancer cells initially increases, and
thereafter decrease.
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Figure 4.3: Tumor control probability when proliferation rate switches randomly, with an
average ρ = 0.5, standard deviation σ = 0.3, n0 = 50, and Γ = 1 for the different switching
rates.
Figure 4.4: Tumor control probability when division rate is switching randomly with ρ =
0.5, n0 = 50, Γ = 1, and different standard deviations for switching rates ν = 0.02 and
ν = 0.2.
Moreover, as σ increases, extinction time distribution is skewed to the right, and the
average extinction time decreases (Figure 4.5). Therefore, Figures 4.4 and 4.5 confirm that
higher variation (σ) is initially beneficial for tumor removal, but reduces the probability
of tumor eradication over time. Increasing σ also modifies the dynamics of cell numbers,
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enhancing their average and variance (Figure 4.6).









Figure 4.5: The average extinction time and extinction time distribution when ρ = 0.5,
n0 = 50, Γ = 1, and different standard deviations for switching rate ν = 0.02.







Figure 4.6: The average and variance of cell numbers with n0 = 50, ρ = 0.5, Γ = 1, and
different standard deviations for switching rate ν = 0.02.
It is important to understand why increasing the standard deviation primarily enhances
TCP, but then reduces the efficiency of treatment over time. Consequently, TCP is cal-
culated when the rate of random fluctuations, ν, is sufficiently small, or when the finite
correlation time, 1/(2ν), approaches infinity. Therefore, the proliferation rate is either
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ρ+ σ or ρ− σ at each realization, and so can be used in cases when a patient’s randomly
assigned cell division rate is one of these two values. Assuming these two specific cases,
TCP can be measured using the analytical solution (equation 4.10), because both birth
and death rates are constant. Figure 4.7 graphs TCP for proliferation rates corresponding
to ρ, ρ + σ, and ρ − σ, respectively. This figure also displays the average tumor control
probability of TCPρ+σ and TCPρ−σ. The lower birth rate ρ− σ results in a greater TCP
value, which eventually saturates to the probability 1 over time. At the same time, the
higher birth rate ρ+σ leads to a lower probability of tumor removal. Therefore, on average,
TCP is controlled by TCPρ−σ before it approaches 1, and thereafter, TCP is determined by
TCPρ+σ. As a result, taking randomness into consideration, TCP can reduce to, at most,
a probability of 0.5, which is the average of the highest and lowest possible probabilities
for division rates ρ− σ and ρ+ σ, respectively, for enough large time t.







Figure 4.7: Tumor control probability obtained from analytical solution with ρ = 0.5,
Γ = 1, σ = 0.4, and n0 = 50.
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In addition, Figure 4.8 shows (TCPρ−σ + TCPρ+σ)/2 evaluated using an analytical
solution for different standard deviations, confirming the same qualitative behavior as
reported when the proliferation rate is changing randomly over time (ν is not small).
Figure 4.8: Tumor control probability obtained from analytical solution with ρ = 0.5,
Γ = 1, n0 = 50, and different standard deviations.
4.3.2 Random death rate
We apply dichotomous Markov noise to describe the death rate Γ(t) = 1
2
[ (k1 + k2) +
ξ(t)(k1 − k2)] and we consider a constant birth rate ρ(t) = ρ. The results for random
death are similar to those explained above for the random birth case (see Figures D.1, D.2,
D.3, D.4, and D.5 in Appendix D). The results indicate that, although higher death rate
controls TCP at first, lower death rate basically governs the probability of tumor removal
later in time.
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4.3.3 Random birth and death rates
Figure 4.9 suggests that randomness in the death rate has more-negative impact on TCP
than randomness in the birth rate. In addition, there is a minimum tumor control prob-
ability, when both proliferation and death rates are changing arbitrarily and they are
anticorrelated (cells with smaller division rates die with higher death rates; conversely,
cells with higher division rates die with lower death rates). TCP improves for cases where
random birth and death rates are autocorrelated; finally, it approaches the TCP with
constant birth and death rates when they are correlated (cells with smaller proliferation
rates die with smaller death rates; in contrast, cells with higher proliferation rates die with
higher death rates)
Figure 4.9: Tumor control probability when division and death rates are switching ran-
domly, with ρ = 0.5, n0 = 50, and Γ = 1 for standard deviations σ = 0.2 and switching
rate ν = 0.02.
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4.3.4 The effect of randomness on TCP for a radiotherapy sched-
ule
Studying the affect of random fluctuations on the performance of the potential clinical
radiotherapy schedules is of practical interest. Fractionated radiotherapy usually splits
the total administered dose into a smaller number of fractions that are given over the
period of several weeks to reduce possible side effects. For instance, the standard regimen
is given once each weekday, with the rest over the weekend. Here, the impact of random
proliferation rate on the effectiveness of the standard schedule is investigated.
The proliferation rate ρ(t) is assumed to switch randomly using the dichotomous
Markov noise. It is also considered that cells can die during the radiation time inter-
val and that the radiation induced cell kill rate follows a linear quadratic model in which
the fraction of cells surviving a dose d is estimated by exp(−αd − βd2) (Hall & Giaccia,
2006). In this formulation, α and β are radiobiological parameters indicating the sensitivity
of cells to the radiation. Thus, the hazard function for a single dose d during a treatment
period ∆T is defined as




















where dj is the dose administered at the j
th fraction of radiation. Here, ∆T is taken to
be 15 minutes, and the chosen radiobiological parameters are α = 0.41 and β = 0.17
(Forouzannia et al., 2018).
The graphs in Figures 4.10 and 4.11 demonstrate the probability of tumor extinction
versus, respectively, the time and dose for different standard deviations (σ) and rates of
random changes (ν). The results show similar behaviors, as reported in subsection 4.3.1,
when the birth rate is changing stochastically and the death rate is constant over time
(Γ(t) = Γ). The results confirm that when the standard deviation (σ) of the proliferation
rate increases, the stochastic changes in the birth rate initially improve the efficiency of the
standard schedule, but ultimately have a negative effect on treatment schedule efficacy over
time and for larger doses. In addition, when the rate of random change, ν, grows, the TCP
comes close to the tumor extinction probability found in the case where the proliferation
rate is constant over time (see Figure 4.10 and Figure D.6 in Appendix D). The same
results are also expected if the cellular death rate between radiotherapy fractionation alters
randomly.
4.3.5 Special cases
TCP quantitatively measures the effectiveness of radiotherapy protocols that result in a cell
kill rate which is higher than the cell proliferation rate, and this has been fully discussed
above. Here, another topic of interest is explored: the impact of random cell birth and
death rates on the extinction probability (EP) for two different cases. In the first, the
average birth rate equals the average death rate, and in the second, the average birth rate
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(a) (b)
Figure 4.10: Tumor control probability for standard radiotherapy schedule with respect to
time when proliferation rate switches randomly, with an average ρ = 0.5, γ = 0, n0 = 300,
and different standard deviations for (a) ν = 0.2 and (b) ν = 0.5.
is greater than the average death rate.
To study the first case, we take an approach similar to that taken in the previous section,
the extinction probability is studied when the proliferation rate ρ(t) (defined based on
dichotomous Markov noise) changes randomly between two values with an average ρ = Γ.
For the case when there is no noise in the system (ρ = Γ), the analytical solution (4.10)
is reduced to p0(t) = (
ρt
1+ρt
)n0 , which approaches 1 when t goes to infinity. The modified
Gillespie algorithm is applied to evaluate the extinction probability when ρ(t) changes
randomly. The results are similar to those studied in the previous section that explored
the extinction probability when the death rate is greater than the birth rate (Figures D.7,
D.8, D.9, D.10 in Appendix D). As σ increases, the extinction probability initially rises.
However, if the population does not become extinct, the probability of extinction decreases
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(a) (b)
Figure 4.11: Tumor control probability for standard radiotherapy schedule with respect to
dose when proliferation rate switches randomly, with an average ρ = 0.5, γ = 0, n0 = 300,
and different standard deviations for (a) ν = 0.2 and (b) ν = 0.5.
thereafter over time as σ gets larger. To better clarify the results, the extinction probability
is evaluated when the random fluctuation rate, ν, is small enough. Therefore, EPρ+σ and
EPρ−σ are calculated for two constant proliferation rates, ρ + σ and ρ − σ, respectively.
The extinction probability is larger for the lower division rate ρ − σ and approaches a
probability of 1 over time. However, the higher proliferation rate ρ + σ corresponds to
the lower extinction probability, which reaches ( Γ
ρ+σ
)n0 for sufficiently large time t, since
ρ+σ > Γ. Thus, the average probability of extinction is initially governed by EPρ−σ, which
goes to 1 over time. Thereafter, on average, the probability of extinction is controlled by
EPρ+σ (Figure D.10 in Appendix D). In addition, both the average and variance of cell
numbers is enhanced as σ escalates. Further, the extinction probability, when Γ(t) is
modified randomly between two numbers with an average Γ = ρ following a dichotomous
Markov noise, displays the same behavior as that for random birth.
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The impact of random fluctuations on the proliferation rate ρ(t) is also investigated for
the second case, in which the average birth rate is greater than the average death rate. The
extinction time distribution is skewed to the right, and the average extinction time reduces
as randomness increases. The results indicate that the extinction probability increases as σ
increases. For further investigation, the extinction probability has been studied when the
finite correlation time ( 1
ν
) is large. Consequently, the extinction probability corresponding
to the proliferation rates ρ + σ and ρ − σ is evaluated. EPρ+σ approaches ( Γρ+σ )
n0 as t




time t if ρ − σ > Γ, but approaches 1 otherwise. As a result, the average of EPρ+σ and
EPρ−σ is mainly influenced by EPρ−σ. Thus, increasing randomness increases the extinction
probability, but the population does not become extinct (Figure D.11 in Appendix D). The
study of random fluctuations in random death also leads to the same results.
4.4 Conclusion and Discussion
In this chapter, a stochastic formulation has been developed to study the impact of random
demographic parameters on tumor control probability (TCP). In this direction, we have
analyzed a simple birth-death model, when birth and death rates are changing randomly
in response to dichotomous Markov noise. Therefore, these rates are defined using random
step functions. Consequently, when calculating TCP, a novel computational approach, a
modified Gillespie algorithm, has been employed to incorporate the effect of radiation-
induced cell kill and arbitrary fluctuations through discontinuous step functions. The
results confirm that higher randomness increases TCP, but thereafter, TCP decreases as
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time passes if the tumor has not been removed completely. Therefore, a higher standard
deviation corresponds to a greater TCP at the beginning and a lower probability of removal
later on. In addition, TCP has been measured when both birth and death rates were being
arbitrarily altered at the same time, lessening the effectiveness of radiotherapy when the
rates are anticorrelated. In general, tumor microenvironmental changes can negatively
influence the performance of radiotherapy protocols. Therefore, therapeutic approaches
should consider these variations and place more emphasis on personalized treatment, since
there is tumor diversity among patients, even with the same cancer types.
Considering a two compartment model consisting of a subpopulation of resistant and
sensitive cells, the stochastic dynamics of the resistant subpopulation is independent of
sensitive cells and can be explained using a simple birth/death model in the absence of
plastic transitions from sensitive cells to resistant cells. The results of this work can be
used to explain the impact of random changes in the birth and death rates of resistant cells
on the probability of a resistant cell’s eradication.
The existence of fluctuation and noise in biological systems has been observed at various
levels from the molecular, to the sub-cellular and organism level, and even at the population
level. Although the effects of noise in biological processes can differ, it has been suggested
that random fluctuations and noise can result in the variation of properties among identical
populations of cells (Schmidt et al., 2012; Tsimring, 2014). For example, experimental
results have shown that environmental noise can induce the production of different levels of
a specific protein in two genetically identical cells (Pilpel, 2011). In addition, although noise
can be beneficial, it may lead to more unfavorable conditions in a biological context. In
particular, bacteria use different strategies that help them to survive under stress conditions
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such as starvation, heat, and antibiotic. For instance, dormant cells can resist antibiotics
and maintain the population growth of bacterias (Schmidt et al., 2012; Tsimring, 2014).
The mathematical model and computational approach explored in this chapter can be used
to study the impact of noise in the response of bacteria and biofilms to antibiotics.
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Chapter 5
The impact of plasticity on tumor
control probability
The most efficacious administration of radiotherapy must be determined in order to deliver
the most potent dose of radiation to the bulk of a tumor while minimizing radiation to the
normal surrounding tissue and so reduce possible side effects. The tumor control probabil-
ity (TCP) is a treatment planning tool that evaluates the probability of tumor eradication
and helps in the assessment of the relative efficiency of different radiotherapy regimens.
The response of tumors to radiation differs greatly even in patients with same types of
cancers. Tumor heterogeneity or cellular diversity among cancer cells has a pronounced
impact on the success of the administered radiotherapy protocols. Tumor heterogeneity
can be explained using the (Cancer stem cells) CSC hypothesis, which posits that CSCs
are responsible for tumor initiation and propagation. CSCs are believed to be the main
cause of therapeutic resistance and metastasis, leading to treatment failure. Moreover, the
76
existence of plasticity or bidirectional transition between CSCs and non-CSCs indicates
that, sometimes, non-CSCs appear to mimic CSC phenotypes, resulting in an increase in
resistance. We have developed a stochastic model to investigate the impact of plasticity
on the efficacy of radiotherapy. The effect of plasticity on TCP is explored by applying
the model on standard, hyperfractionated, and accelerated hyperfractionated radiother-
apy schedules. Results confirm that tumor control becomes more difficult in the presence
of plasticity. It is also observed that the impact of plasticity on accelerated hyperfrac-
tionated schedules is marginal, although the efficiency of this radiotherapy protocol drops
considerably with highly resistant tumors. In addition, the combination of radiotherapy
and targeted therapy increasing CSC differentiation, improves both the probability of CSC
and tumor removal in the absence of plasticity. However, in the presence of plasticity, the
effect of the combination therapy is not significant.
5.1 Introduction
Tumor heterogeneity, which arises due to genetic and phenotypic diversity as well as en-
vironmental differences among cancer cells, has a fundamental impact on treatment out-
comes. In particular, the resistance of CSCs to radiotherapy can lead to treatment failure
and tumor recurrence (Forouzannia & Sivaloganathan, 2017; Hanahan & Weinberg, 2011).
This cellular diversity has been observed between different patients and within a single
tumor. The cancer stem cell (CSC) hypothesis proposes that tumor growth is governed
by a scarce subpopulation of cancer cells (CSCs) undergoing symmetric and asymmetric
proliferation to regenerate themselves and produce other lineages of cancer cells, thus, con-
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tributing to intra-tumor heterogeneity. Furthermore, biological observations indicate that
sometimes non-CSCs display CSC properties, suggesting some degree of plasticity between
CSCs and non-CSCs (Marjanovic et al., 2013a,b). Several mathematical models have been
developed to incorporate the effect of plasticity in cancer cell dynamics and mammosphere
formation assays (Forouzannia et al., 2018; Gupta et al., 2011; Tonekaboni et al., 2017;
Turner & Kohandel, 2010; Zapperi & La Porta, 2012). However, the impact of plasticity
on the effectiveness of radiotherapy protocols has not been investigated, and this is the
direction we study in this chapter.
A large proportion of patients who are suffering from cancer receive radiation therapy
as part of their treatment. The aim of radiotherapy is to achieve a high probability of local
tumor control at a low risk of associated side effects. TCP is a measurement that is defined
as the probability of tumor-cell extinction by the end of the treatment. Consequently,
TCP can be used to evaluate the performance of potential radiotherapy protocols and
suggest the one with an optimum outcome. Several mathematical and computational
approaches have been developed in the literature to study TCP (Dawson & Hillen, 2006;
Gong, 2011; Kendal, 1998; Tucker et al., 1990; Yakovlev, 1993; Zaider & Hanin, 2011;
Zaider & Minerbo, 2000). Stochastic models based on Poisson statistics have been used to
investigate the probability of tumor control. One important model considers a simple birth/
death master equation that includes the stochastic effect of cell kill due to radiation. Thus,
TCP is defined as the probability of no cells remaining at the end of treatment (Zaider
& Minerbo, 2000). The model is based on clonal evolution theory, which claims that
carcinogenesis arises due to random mutations that occur in a single cell. But, based on
the CSC hypothesis, the elimination of CSCs is essential to achieve a cure, since the CSCs
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are capable of initiating and reestablishing tumor growth. Thus, Dhawan et al. (2014)
developed a unidirectional hierarchical model (based on the CSC hypothesis) to determine
the probability of eliminating CSCs from a heterogeneous cell population. However, the
model does not consider the plasticity between non-CSCs and CSCs.
Here, we develop a stochastic model based on the CSC hypothesis to study the impact of
plasticity on tumor control probability. The radiation induced cell kill rate is assumed to be
different between CSCs and non-CSCs, to account for the various radiosensitivities among
cancer cells. The cancer kill rate is also considered to be a step function such that the
kill rate is high during radiation and lower otherwise. Moreover, calculating the analytical
solution is not feasible in the presence of plasticity. Thus, a modified Gillespie algorithm
for the reactions with rates changing discontinuously is used to solve the time evolution of
the stochastic model and calculate the TCP. Consequently, the probability of CSC removal
(TCPS) and the probability of tumor eradication (TCS+P) are evaluated for three different
radiotherapy schedules: standard, hyperfractionated, and accelerated hypefractionated. In
addition, TCPS and TCS+P are calculated for a therapy that combines radiotherapy and
the targeted therapy in the presence and absence of plasticity. The results indicate that
the accelerated hypefractionated schedule obtains the best probability of CSC and tumor
removal. Yet, both TCPS and TCS+P noticeably decrease for the most resistant tumors.
Furthermore, applying combination therapy does not substantially improve the control of
either the CSC population or tumor in the presence of plasticity.
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5.2 Method
This Chapter investigates how plasticity between progenitors and CSCs affects TCP. For
this purpose, a two compartment model is designed by splitting the total population of
cells into sub-populations of stem cells (S) and progenitor cells (P ). Stem cells have the
potential to go through numerous cell divisions to replicate themselves and to replace
progenitors. Furthermore, it is assumed that there is a degree of plasticity in the system
and that progenitors can revert to stem cells. In addition, cells can die independently of
each other at a rate of Γi, for i = S, P, (stem cell, progenitor). Therefore, we can consider
the following division pathways.
S → S + S : ρS,
S → P : ρSP ,
P → P + P : ρP ,
P → S : ρPS,
S → 0 : ΓS(t),
P → 0 : ΓP (t),
(5.1)
where ρS and ρP are, respectively, the rates of self renewal for stem cells and proliferation for
progenitors. In addition, stem cells can replace progenitors at rate ρSP , and progenitors
can replace stem cells at rate ρPS. Cells can die at rate Γi(t), for i = S, P, (stem cell,
progenitor).
CSCs are capable of unlimited proliferation to maintain a tumor. Furthermore, they dis-
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play resistance to radiotherapy through unregulated radiation-induced DNA repair mech-
anisms after exposure to treatment. Thus, the elimination of CSCs is essential to control
a tumor. Consequently, the probability of eradicating CSCs is a key element in measuring
the effectiveness of any particular treatment. In this context, the elimination of CSCs when
no plasticity exists in the tumor (i.e. ρPS = 0) can lead to tumor control. The study of
the probability of CSC removal in model 5.1 with ρPS = 0 is equivalent to analyzing the
extinction probability in a simple birth/death process, and is independent of the dynamics
of progenitors (as seen in Dhawan et al., 2014) and briefly explained in Appendix E. In
the presence of plasticity, however, the removal of CSCs may not result in tumor control.
The stochastic dynamic of model 5.1 is described using the following probability dis-
tribution function for a population of nS stem cells and nP progenitors at time t with the
initial condition pnS ,nP (t0) = δnSnS0δnPnP0 . Here, nS0 and nP0 denote the number of stem
cells and progenitors at time t0.
dpnS ,nP (t)
dt
= ρSpnS−1,nP (t)(nS − 1) + ρSP (nS + 1)pnS+1,nP−1(t) + ρP (nP − 1)pnS ,nP−1(t)
+ ρPS(nP + 1)pnS−1,nP+1(t) + ΓS(nS + 1)pnS+1,nP (t) + ΓP (nS + 1)pnS ,nP+1(t)
− (ρS + ρSP + ΓS)nSpnS ,nP (t)− (ρP + ρPS + ΓP )nPpnS ,nP (t).
(5.2)






iP j, we obtain
∂U(S, P, t)
∂t
= [(S − 1)(ρSS − ΓS(t)) + (P − S)ρSP ]
∂U(S, P, t)
∂S











The derivation of an analytical solution for equation 5.3 is not possible. In addition,
the cancer cell death rates are defined as step functions in which the radiotherapy-induced
cancer kill rate is higher in each exposure duration and lower otherwise. Thus, the modified
Gillespie algorithm (Shahrezaei et al., 2008) is employed to evaluate TCP in the presence
of discontinuous death rates changes.
The radiation induced cell kill is assumed to occur directly in time intervals when
fractions of radiation are given. It is also suggested that CSCs are less likely to die than
progenitors, due to the former’s resistance to the therapy. Therefore, the cell kill rate at
each treatment time interval ∆T and given dose d is defined as







with different radiobiological parameters αi and βi (i ∈ {S, P}) for CSCs and progenitors.
The hazard function fi(t, d) is developed based on a linear quadratic model, and cell
survival after each fraction can be deduce by exp(−αid − βid2), (i ∈ {S, P}) (Hall &
Giaccia, 2006). Thus, the cell death rates for CSCs and progenitors (i ∈ {S, P}) can be









t ∈ [tj, tj + ∆T ],
0 otherwise,
(5.5)
where tj and dj are the initial time and the given dose of the j
th fraction of radiotherapy,
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respectively. The values of model 5.1 and radiosensitivity parameters are selected from
(Forouzannia et al., 2018). Thus, ρS = 0.1, ρSP = 0.7, ρP = 0.2, ρPS = 0.05 and
radiobiological parameters are αS = 0.14, αP = 0.41, βS = 0.048, and βP = 0.17. The
duration of treatment at each fraction of radiation ∆T is assumed to be 15 minutes.
5.3 Results and Discussion
Radiotherapy targets cancer cells and shrinks tumors, but CSCs are apt to escape the effect
due to their resistance to radiation. In general, tumors rich in CSCs are very difficult to
control relative to ones with a lower CSC fraction. Consequently, studying the efficiency
of radiotherapy protocols for eradicating CSCs is important. However, removing the CSC
population may not be sufficient to control the disease in the presence of plasticity. There-
fore, to investigate the impact of plasticity on tumor control, we evaluate the probability
of CSC removal, TCPS, and the probability of tumor eradication, TCPS+P , for model 5.1
in the presence and absence of plasticty.
In this direction, TCPS and TCPS+P are compared for standard (ST), hyperfraction-
ated (HR), and accelerated hyperfrationated (AC) radiotherapy schedules over three weeks
of treatment. The conventional treatment regimen delivers a dose of 2 Gy per fraction,
once each weekday. For the hyperfractionated and accelerated hyperfrationated protocols,
the respective doses of 1.2 Gy and 1.5 Gy are given twice each weekday.
Figure 5.1 represents TCPS and TCPS+P , applying a standard radiotherapy regimen
in both the presence and absence of plasticity in the system. The curves are relatively
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close to each other in Figure 5.1a due to the high radiotherapy-induced cell kill rates.
Consequently, the cell kill rates at each fraction of radiation are reduced by assuming that
βS and βP equal zero, to better distinguish the differences between various possible cases
(Figure 5.1b). The results confirm that both TCPS and TCPS+P reduce when non-CSCs
are able to behave like CSCs.
(a) (b)
Figure 5.1: TCPS and TCPS+P for a standard radiotherapy schedule in the absence and
presence of plasticity with initial numbers of cells n0S = 100 and n
0
P = 100. (a) αS = 0.14,
αP = 0.41, βS = 0.048, and βP = 0.17. (b) βS = 0 and βP = 0.
In Figure 5.2, TCPS and TCPS+P are compared for standard, hyperfractionated, and
accelerated hyperfactionated protocols. Whether or not plasticity exists, accelerated hy-
perfractionated and standard protocols correspond, respectively, to the largest and lowest
TCPS and TCPS+P . In general, the existence of plasticity leads to a smaller probability
of CSC and tumor removal for these three radiotherapy schedules. The probability of CSC
removal is relatively close for these three radiotherapy schedules in the absence of plasticity,
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but the calculated TCPS is more distinct in the presence of plasticity (Figure 5.2a). Fur-
thermore, Figure 5.2a reveals that the difference between the calculated values for TCPS
with and without plasticity are much less for the accelerated hyperfractionated schedule
than for the other two, indicating that the existence of plasticity does not substantially
impact the accelerated hyperfractionated schedule’s effectiveness. The same trend is also
observed for TCPS+P (Figure 5.2b).
(a) (b)
Figure 5.2: (a) TCPS and (b) TCPS+P with respect to time for standard, hyperfraction-
ated, and accelerated hyperfractionated schedules in the absence and presence of plasticity.
The initial numbers of cells are n0S = 100 and n
0
P = 100.
Figure 5.3 is the graph of (a) the probability of CSC and (b) tumor extinction with
respect to dose in the presence and absence of plasticity. The results confirm that a
larger total dose is required for CSC and tumor extinction in the presence of plasticity.
Furthermore, comparing 5.2 and 5.3 shows that although the accelerated hyperfractionated
schedule achieves a higher probability of CSC and tumor removal than the other two
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(a) (b)
Figure 5.3: (a) TCPS and (b) TCPS+P with respect to dose for standard, hyperfraction-
ated, and accelerated hyperfractionated schedules in the absence and presence of plasticity.
The initial numbers of cells are n0S = 100 and n
0
P = 100.
schedules over time, this protocol uses a larger total dose of radiation to obtain the same
TCPS and TCPS+P .
In addition, increasing the plasticity in the tumor decreases the TCPS and TCPS+P ,
implying greater challenges in controlling the disease (Figure F.1 in Appendix F). In Figures
5.4 and 5.5, TCPS and TCPS+P are graphed to explain the impact of a highly resistant CSC
subpopulation on treatment efficiency in both the presence and absence of plasticity. The
results confirm that reducing the sensitivity of CSCs to radiation yields a lower probability
of control of both the CSC subpopulation and tumor. Consequently, radiotherapy protocols
are much less efficient against highly resistant tumors than less-resistant ones (Figures 5.4
and 5.5). In particular, the performance of the accelerated hyperfractionated protocol
drops enormously. Furthermore, the probability of CSC eradication is comparatively close
for standard, hyperfractionated and accelerated hypefractionated schedules when plasticity
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does not exist in a tumor (Figure 5.4a). Consequently, increasing the number of fractions
does not improve the probability of CSC removal for extremely resistant tumors in the
absence of plasticity.
(a) (b)
Figure 5.4: (a) TCPS and (b) TCPS+P for standard, hyperfractionated, and accelerated hy-
perfractionated schedules in the absence of plasticity for different radiosensitivities among
CSCs.
It is necessary to understand that CSC removal can ultimately contribute to tumor
control when there is no plasticity in the system, although expecting this absence may not
be biologically realistic. CSC elimination is not enough to attain a cure when plasticity
exist, but is still important in decreasing the most-resistant subpopulation of cells. Conse-
quently, it is crucial to consider TCPS+P as a measure for evaluating therapeutic regimen
efficiency in the presence of plasticity, while simultaneously monitoring CSC elimination.
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(a) (b)
Figure 5.5: (a) TCPS and (b) TCPS+P for the three radiotherapy protocols in the presence
of plasticity for different radiosensitivities among CSCs. The initial numbers of cells are




Experimental results suggest that the fraction of CSCs increases following ionizing radia-
tion, due to the resistance of this subset of cells to the therapy (Bao et al., 2006; Lagadec
et al., 2010). This frequently results in relapse and treatment failure. In this direction,
both in vitro and in vivo experiments have shown that certain bone morphogenetic pro-
teins (BMPs) are capable of inducing positive biomarker cells (stem-like cancer cells) to
differentiate into negative biomarker cells (non-CSCs) in brain tumors (Piccirillo et al.,
2006). Consequently, applying this targeted strategy is expected to escalate the differ-
entiation of radioresistant cells into non-CSCs that are more sensitivite to radiation and
have less tumorigenic potential. Therefore, a reduction in the CSC pool can contribute to
better therapeutic outcomes. However, the plastic transition from non-CSCs to CSCs can
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reverse the process and diminish the impact of BMPs. Thus, it is of interest to investigate
the impact on TCP increasing CSC differentiation rates in the presence and absence of
plasticity, which will be discussed next.
Here, we consider three types of combination treatments over 15 days, consisting of
10 fractions of radiation (the dose of 2Gy is administered per fraction once a day) and
5 days of targeted strategy that trigger CSCs to differentiate into non-CSCs. The first
protocol includes 10 days of radiation, followed by a targeted strategy of increasing the
differentiation rate ρSP for 5 days (scheme 1). The second starts with 5 days of increasing
CSCs differentiation, followed by 10 days of radiation (scheme 2). Finally, the third involves
5 days of radiation, followed by 5 days of targeted therapy, and last, another 5 days of
radiation (scheme 3). We consider a base protocol for each of these three schedules, denoted
as schemes 1-b, 2-b, and 3-b, in which the ρSP does not change.
Figure 5.6 shows TCPS and TCPS+P for schemes 1-b, 2-b, and 3-b in the absence
and presence of plasticity. As explained in the previous section, both TCPS and TCPS+P
decrease when plasticity exists. Comparing the results for these three schedules indicates
that the minimum TCPS and TCPS+P are obtained by scheme 1-b, suggesting that a
large gap between fractionations reduces the probability of CSC and tumor removal (Solid
and dashed black curves) in the absence and presence of plasticity. In addition, scheme
3-b reports the highest TCPS+P , but this schedule does not lead to the best control of
the CSC population (solid and dashed red curves). Employing the targeted therapy in
combination with the radiotherapy (schemes 1–3) shows an improvement in TCPS and
TCPS+P for scheme 2 when plasticity does not exist, with the most increase occurring
in the former (TCPS). However, the impact of targeted therapy on schemes 1 and 3 is
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limited, with almost no increase in TCPS+P for either of the schemes (Figures 5.6a and
5.7a ). On the other hand, combining the targeted therapy with radiation in the presence
of plasticity enhances TCPS and TCPS+P somewhat for schemes 1–3, with almost no
increase in TCPS+P for scheme 1 (Figures 5.6b and 5.7b). Similar trends are also observed
when ρSP increases to 2.1. In Figure 5.7b, TCPS decreases over a short period of time
and increases after for scheme 3. This behavior occurs because reducing ρSP after 10 days
in the presence of plasticity decreases CSC elimination. Consequently, the generation of
CSCs from progenitors can reduce the probability of complete CSC removal.
(a)












Figure 5.6: TCPS and TCPS+P for schemes 1-b, 2-b, and 3-b in the (a) absence and (b)
presence of plasticity, with initial numbers of cells n0S = 100 and n
0
P = 100.
The above results demonstrate that increasing ρSP before radiotherapy has the most
effect in improving the probability of CSC removal in the absence of plasticity. In addi-
tion, the probability of tumor control increases in this case. However, in the presence of
plasticity the tumor control is complicated, and even triggering CSCs to differentiate does
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Figure 5.7: TCPS and TCPS+P for schemes 1, 2, and 3 in the (a) absence and (b) presence
of plasticity, with initial numbers of cells n0S = 100 and n
0
P = 100. ρSP is increased to 1.4
during targeted therapy.
not enhance TCPS and TCPS+P significantly. Nevertheless, increasing CSC differentiation
before radiotherapy leads to better tumor removal control. But TCPS is still less than
the case when CSC differentiation increases after radiotherapy. In general, these outcomes
confirm that understanding the heterogeneity of tumors is important in order to develop
optimum protocols.
5.4 Conclusion
Here, we have presented a stochastic model to investigate the impact of plasticity on the
tumor control probability. The radiation induced cell kill rate has been modeled using
a step function in which the cancer cell kill rate is high during radiotherapy and lower
otherwise. Therefore, the time evolution trajectory of a hierarchical stochastic model
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consisting of CSCs and progenitors has been calculated using a modified Gillespie algorithm
for rates that are changing discontinuously. Thus, TCPS and TCS+P are defined as the
probability of removing CSCs and the probability of eliminating a tumor, respectively.
The response of cancer cells to the radiation varies among cancer cells with, CSCs showing
more resistance to the treatment. TCPS and TCPS+P have been computed for standard,
hyperfractionated, and accelerated hyperfractionated protocols. The results suggest that
TCPS and TCPS+P are reduced in the presence of plasticity under these three radiotherapy
schedules. In the presence and absence of plasticity, the best control is achieved by the
accelerated hyperfractionated regimen. The existence of plasticity between non-CSCs and
CSCs does not greatly affect TCP for the accelerated hyperfractionated protocol. However,
the effectiveness of the accelerated hyperfactionated regimen is also decreased significantly
for highly resistant tumors. The lower sensitivity to radiation among CSCs also contributes
to a lower probability of CSC and tumor removal. The results also confirm that combination
therapy can improve TCPS and TCPS+P in the absence of plasticity, with the most increase
in the former. However, combination therapy does not increase the probability of CSC and
tumor removal appreciably when plasticity exists.
The results indicate that cellular heterogeneity and the existence of plasticity in a tumor
significantly impact the efficacy of treatment. Thus, it is important to consider this cellular
diversity when determining an appropriate treatment protocol.
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Chapter 6
The impact of plasticity and negative
feedback regulation on sphere
formation ability
CSCs are at the apex of a cancer cellular hierarchy and possess high tumorigenic potential
to reproduce themselves and their progeny which form the bulk of a tumor. Moreover, it
has been suggested that this hierarchical structure is not unidirectional; there is degree
of plasticity between CSCs and progenitor cells. The presence of tissue homeostasis is
maintained through cellular mechanisms and regulatory feedback, whose inhibition may
lead to tumor growth. For example, several mathematical studies have suggested that
disruption of the negative feedback controlling CSC proliferation and dedifferentiation
rates can lead to tumor growth in a large cellular population. In this chapter, we apply the
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Gillespie algorithm to investigate the effect of negative regulatory feedback on the ability
of a single CSC to form a sphere. The results suggest that both sphere formation efficiency
(SFE) and average sphere size (AVSS) decrease when CSC division and the process of
dedifferentiation are regulated by negative feedback.
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6.1 Introduction
In healthy tissue, stem cells have the ability to undergo protracted selfrenewal, and to
generate progenitors with limited proliferation potential that finally produce terminally
differentiated cells. Therefore, the maintenance of tissue homeostasis is governed by the
regulatory mechanisms of positive and negative feedback loops that are properly governed
based on tissue requirements. For example, the regulatory feedback that prevents CSC
symmetric and asymmetric division is crucial to maintaining tissue homeostasis (Biteau et
al., 2011; Rodriguez-Brenes et al., 2011; Watt & Hogan., 2000).
Based on the CSC hypothesis, tumors also consist of a hierarchal structure in which
CSCs are capable of reproducing themselves, progenitors, and other cell lineages, resulting
in tumorigenesis. Recent evidence suggests that sometimes non-CSCs behave like CSCs,
implying a degree of plasticity among tumor cells (Cabrera et al., 2015; Gupta et al.,
2011; Hanahan & Weinberg, 2011; Kreso & Dick, 2014; Marjanovic et al., 2013a,b). In
addition, it has been proposed that escaping from feedback loops plays an important role
in the process of carcinogenesis (Vogelstein et al., 2004; Wodarz, 2018). For example, in
healthy tissues, the high number of differentiated cells keeps the process of plasticity under
control, and dedifferentiation can occur in cases of injury and tissue damages (Stange et
al., 2013; Yanger & Stanger, 2014). Consequently, disruption of the negative feedback
that controls plasticity can lead to an increased number of CSCs with high tumorigenic
potential. Therefore, it is clearly of interest and importance to investigate the impact of
plasticity on tissue homeostasis.
Several mathematical models have been developed based on the CSC hypothesis, to
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explore and develop an understanding of multiple different important factors driving the
process of tumorigenesis, therapeutic resistance, and treatment optimization (Anderson
& Quaranta, 2008; Enderling & Hahnfeldt, 2011; Forouzannia & Sivaloganathan, 2017;
Werner et al., 2016). In addition, the impact of plasticity on cancer progression and ther-
apeutic outcomes has also been investigated in the literature recently (Forouzannia et al.,
2018; Jilkine & Gutenkunst, 2014; Mahdipour et al., 2017; Tonekaboni et al., 2017). There
is also work on the effects of negative feedback on CSC differentiation and dedifferentia-
tion in a large population of cells in the literature (Rodriguez-Brenes et al., 2011; Wodarz,
2018). However, negative feedback has not been investigated in a stochastic context. In
this chapter, we explore the impact of negative feedback regulators that progenitors secrete
during CSC division and the negative feedback that CSCs trigger during in the process of
plasticity for a small number of cells. For this purpose, a stochastic Gillespie algorithm is
applied to study the negative feedback regulation on the ability of a single cell to generate
a sphere.
6.2 Method and discussion
We consider a simple mathematical model that describes the dynamics of tumor tissues,
composed of a hierarchical population of cells. The model is constructed by splitting the to-
tal cancer cell population into sub populations of cancer stem cells (CSCs) and progenitors.
CSCs (S) proliferate at a rate ρS and undergo symmetric and asymmetric selfrenewal with
probabilities r1 and r2, respectively. CSCs also generate two progenitor cells (symmetric
commitments), with a probability of r3, and so r1 + r2 + r3 = 1. Furthermore, progenitors
96
are capable of switching phenotypically into CSCs at a rate ρPS. It is also assumed that
progenitors can die at rate ΓP , but CSCs are considered not to go through apoptosis due
to their prolonged survival potential. Therefore, the dynamics of the cancer cells can be
mathematically represented by the following division pathways.
S → S + S : ρSr1,
S → S + P : ρSr2,
S → P + P : ρSr3,
P → S : ρPS,
P → 0 : ΓP ,
(6.1)
In addition, the dynamics of stem cells and progenitors are governed by the following
differential equations for large numbers of cells.
dS
dt
= ρS(r1 − r3)S + ρPSP
dP
dt
= ρS(r2 + 2r3)S − (ρPS + ΓP )P.
(6.2)
The model can be reduced to the one discussed in (Wodarz, 2018), by assuming r2 = 0, and
so r3 = 1 − r1. It has been suggested that progenitors imply a hidden negative feedback,
in which increasing the number of progenitors decreases the proliferation rate of CSCs




and ρS is replaced by ρS =
ρS
1+h2Pk2
with the positive constants h1, h2, k1,
and k2.
Clearly, in the absence of plasticity, ρPS = 0, and when there is no feedback in the sys-
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tem, the solutions become extinct for r1 < 0.5, undergo exponential growth for r1 > 0.5,
and converge to equilibrium (tissue homeostasis) for r1 = 0.5. The results show that tissue
homeostasis occurs when r1 > 0.5 if progenitors secrete negative feedback regulators that
impact the CSC division rate and the probability of CSC symmetric division. In addi-
tion, in the presence of plasticity when there is no feedback in the system, the population
grows when r1 > (ΓP − ρPS)/2ΓP , which implies the presence of a population for r1 > 0 if
the dedifferentiation rate is greater than the death rate for progenitors (ρPS > ΓP ). The
number of cells converges to equilibrium if r1 and ρS are subject to negative feedback and
ρPS < ΓP . However, if ρPS > ΓP , the population grows even in the presence of nega-
tive feedback regulators affecting CSC proliferation. On the other hand, if increasing the




), tissue homeostasis is possible even when ρPS > ΓP . In this direction
the results also confirm that if ρPS < ΓP and r1 < 0.5, negative feedbacks regulators in
both CSCs division and plasticity need to be removed for the population to grow (Wodarz,
2018). It also can be observed that if only r1 > 0.5, the negative feedback on CSC prolif-
eration is necessary for tissue maintenance, but if only ρPS > ΓP , the negative feedback
on the plasticity rate is crucial for tissue homeostasis.
In the next section, employing a Gillespie algorithm we explore the impact of negative
feedback regulation on a small number of such populations.
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6.2.1 Negative feedback impacts on sphere forming efficiency
Sphere forming efficiency is a measurement used to evaluate the ability of stem cells or early
progenitor cells to form a sphere. The related experimental protocols are usually designed
based on the purpose of the study, but nearly all these protocols start with seeding cells in a
well such that they are properly dispersed and then allowing them to grow. These cultured
cells are considered to be a sphere when they reach a certain size. Here, we investigate the
impact of negative feedback on sphere formation efficiency and on the average sphere size,
both in the presence and absence of plasticity.
As discussed above, the sphere formation experiment monitors the cell proliferation ca-
pacity by harvesting single cells. Thus, because stochastic simulations are well established
approaches to studying the evolution of small populations, the Gillespie algorithm is used
to simulate the ability of a single CSC to form a sphere. Initially, the simulation considers
cellular pathway 6.1 with no plasticity (ρPS = 0). The procedure is initiated by choosing
the number of single CSCs that are seeded in a well, and so the initial condition is S0 = 1
and P0 = 0. These single CSCs are allowed to grow for 10 days, and are said to have
generated a sphere if the total number of cells produced from each of these single cells hits
set goal of 50 plus cells. Therefore, the sphere formation efficiency is defined as the fraction
of the number of single stem cells that are able to form a sphere, and the average sphere
size equals the total number of cells divided by the total number of single stem cells that
reach 50 and above. The SFE and AVSS for different possible cases of negative feedback
are reported in Table 6.1.
The results (Table 6.1) confirm that the ability of a single CSC to form a sphere and the
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average sphere size are reduced when the division rate ρS is subject to negative feedback.






also results in a decrease of SFE
and AVSS. However, the SFE and AVSS slightly increase if progenitors secret factors that
reduce a negative feedback affecting the symmetric commitment rate r3. The reduction
in r3, in which one CSC is replaced with two progenitors, leads to a reduction in the
population of CSCs. Consequently, it can be observed that a lower r3 rate results in less
CSC death, showing the importance of CSCs in sphere formation. Furthermore, replacing
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(g1 = g4 = 0.03, n1 = n4 = 1) 0.024 58.26
Table 6.1: The sphere formation efficiency and average sphere size in the absence of plas-





















































































(g5 = 0.03, n5 = 1) 0.21 79.1
Table 6.2: The sphere formation efficiency and average sphere size in the presence of





















































































(g5 = 0.03, n5 = 1) 0.32 85.56
Table 6.3: The sphere formation efficiency and average sphere size in the presence of
plasticity when ρS = 0.9, r1 = 0.3, r2 = 0.6, r3 = 0.1, ρPS = 0.1 and ΓP = 0.1
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The results in Tables 6.2 and 6.3 show an increase in both the SFE and AVSS in the
presence of plasticity. Here, similar to the case with no plasticity, the negative feedback
on each of ρS, r1, and r2 leads to a reduction in SFE and AVSS. The SFE and AVSS are
slightly increased if negative feedback is applied to the symmetric commitment rate r3. In
addition, the impact of negative feedback regulators secreted from CSCs, which reduces
the dedifferentiation rate ρPS, is studied, showing minor reductions in SFE and AVSS. The
error for SFE and AVSS are σSFE = 0.00058 and σAV SS = 0.14, respectively, when there
is no plasticity and feedback in the system. The error corresponding to the other cases is
also similar.
6.3 Conclusion
In this chapter we have investigated how negative feedback controlling CSC proliferation
and plasticity affects the ability of a single cell to form a sphere. To do so, the trajectories
of cell numbers undergoing different cellular proliferation pathways have been calculated
using a Gillespie algorithm. Previous studies have shown that such negative feedback on
CSC division and dedifferentiation has an important role in the maintenance of tissue
homeostasis in large cell populations. The results in this chapter show a decrease in sphere
formation capacity and average sphere size when CSC division and dedifferentiation are
subject to negative feedback. The SFE and AVSS are increased if the probability of the
symmetric commitment division pathway in which a single CSC generates progenitors
undergoes negative feedback. Consequently, the increasing number of progenitors in the
tumor reduces the rate of symmetric commitments, corresponding to lower CSC death,
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underlying the importance of CSCs in SFE and AVSS. In addition, the results show that





This thesis has introduced mathematical models developed to study the impact of tu-
mor heterogeneity and microenvironmental changes on the performance of radiotherapy
schedules. In this direction, Chapter 1 introduced the necessary background on tumor het-
erogeneity and tumor microenvironments as well as the underlying mechanisms explaining
radiation induced cell kill. Chapter 2 reviewed the role of the CSCs in therapeutic resis-
tance and new treatment approaches, and Chapter 3 presented a deterministic model for
exploring the effect of radiotherapy on the resistant subpopulation of cells. In Chapters
4 and 5, stochastic models have been developed to study the impact of random birth and
death rates, and plasticity on tumor control probability. In addition, the effect of negative
regulatory feedback on sphere formation efficiency and average sphere size were explored
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in Chapter 6.
In Chapter 2, we comprehensively reviewed mathematical models that probe the impact
of CSCs on therapeutic approaches. CSCs benefit from the development of upregulated
DNA repair mechanisms and underlying cellular pathways that support CSCs resulting
in the emergence of resistance to therapeutic kill agents. Furthermore, this resistant sub-
population is potentially tumorigenic, which enables them to regrow and lead to relapse.
Mathematical modeling is a useful approach for understanding these complicated biological
mechanisms grounded on valid experimental observations on a par with other experimental
techniques. In this direction, we also discussed mathematical models exploring various
CSC properties, and their role in developing new treatment strategies targeting CSCs, and
optimizing treatment outcomes. Cancer biology is extremely complex with many unknown
parameters that need to be identified and understood. Mathematical and computational
approaches can be applied to find the most important parameters and mechanisms using
experimental results. In addition, they can suggest new experimental studies that may
explain related biological questions, ultimately resulting in therapeutic improvements.
In Chapter 3, a simple mathematical model has been presented to study the impact
of radiotherapy on tumor heterogeneity. According to the numerical results, fractionated
radiotherapy can increase the fraction of CSCs and change the cellular diversity of tumors.
Most proposed radiotherapy regimens aim to reduce tumor bulk. However, our results
suggest that the impact of radiotherapy schedules on the population of CSCs needs to
be well understood since the enrichment of CSCs after treatment, can lead to relapse.
Thus, in addition to decreasing tumor size, optimal radiotherapy protocols should control
the CSC population and inhibit the increase of this resistant subpopulation of cells. The
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results suggest that the standard schedule is not the best treatment protocol, and highlights
the need to improve this conventional approach. The optimum regimen for PDGF-driven
glioblastoma suggested in the literature is not validated by our model, which has been
parametrized using breast cancer data. This observation indicates that optimization may
be affected by model design and model dependent parameters. Furthermore, due to the
biological diversity among different cancer types (and even for the same cancer type in
different patients), there may not exist one general optimum schedule that leads to the
best outcomes for all cancers. Consequently, devising personalized therapeutic approaches
would be the preferable route, but can not currently be accomplished on a large scale.
Thus, further work towards reaching this goal is of critical importance.
In Chapter 4, we have investigated the impact of random microenvironmental changes
on tumor control probability by applying stochastic models. In this direction, the effect
of random parameter changes was described using step functions. A modified Gillespie
algorithm for discontinuous changes was therefore applied to calculate TCP. Tumor control
probability was calculated for demographic rates randomly altered over time. An increase
in standard deviation (σ) initially leads to a corresponding increase in TCP. However, TCP
diminishes overtime if it does not saturate to 1, degrading the efficiency of the radiotherapy.
Furthermore, the effectiveness of radiotherapy protocols change significantly when birth
and death rates are anticorrelated and modified arbitrarily.
In Chapter 5 the effect of plasticity on TCP is explored. To do so, a stochastic model
consisting of a population of CSCs and progenitors was considered, in which cell kill rates
due to radiation are described using a step function to account for the higher kill rate
during fractionation. Using a modified Gillespie algorithm, TCPS and TCPS+P , which
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are, respectively, the probability of CSC elimination and tumor removal were computed to
explore the performance of standard, hyperfractionated, and accelerated hyperfractionated
protocols. The results confirm a reduction in both the TCPS and TCPS+P in the pres-
ence of plasticity. In addition, an accelerated hyperfractionated schedule results in better
control than the standard and hyperfractionated regimens, with or without plasticity. It
was also observed that the existence of plasticity does not impact the accelerated hyper-
fractionated protocol’s efficiency significantly. However, both TCPS and TCPS+P drop
noticeably for the accelerated hyperfractionated protocol in the case of highly resistant
tumors. The impact of plasticity on combination therapy that includes targeted therapy
triggering CSCs differentiation and radiotherapy has also been studied. The results show
that the probability of CSC and tumor removal is not enhanced greatly in the presence of
plasticity.
In Chapter 6, both the sphere formation efficiency and average sphere size are stud-
ied for a system of cellular pathways, subjected to regulatory negative feedback on CSC
proliferation and plasticity. A Gillespie algorithm has been used to study the trajectory
of cell numbers under negative regulatory feedback. The sphere formation efficacy (SFE)
and average sphere size (AVSS) decrease when CSC division and dedifferentiation are reg-
ulated through negative feedback. However, if the probability of symmetric commitment is
subject to negative feedback, both the SFE and AVSS are increased, due to the reduction
in CSC death. Furthermore, SFE and AVSS are decreased when the rate of plasticity is
controlled through negative feedback, and so inhibition of this feedback enhances sphere
formation capacity.
In summary, in this thesis, the effect of both cellular heterogeneity and microenviron-
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mental fluctuations on radiotherapy protocols have been investigated. The question of
how regulatory feedback on cellular division pathways affects sphere formation capacity
was also explored. The results show that increasing fractionation in radiotherapy proto-
cols modifies the heterogeneity of tumors. In addition, the existence of plasticity, which
allows transition between CSC and non-CSC compartments, reduces the efficiency of ra-
diotherapy protocols as well as of combination therapy (targeted therapy increases CSC
differentiation and radiotherapy). The random fluctuations of cellular demographic factors
have also been shown to influence the tumor control probability. Finally, the results con-
firm that avoiding the effects of the regulatory negative feedback controlling CSC division
and dedifferentiation rates, increases the ability of a single CSC to form a sphere.
7.2 Future work
This section describes a future avenue for the author’s research. This future work will
tackle some of the prospective points of the current work as well as an ongoing project
on second cancer risk estimation. Overall, the main areas for potential future work are as
follows.
7.2.1 Prospective future work
The impact of radiotherapy on tumor heterogeneity, investigated in Chapter 3, assumed
different radiosensitivities among cancer cells as well as dose dependent transition rates
from the repair phase to the active non repairing population. The model can be extended
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to consider more biological determinants, such as an increase in the selfrenewal ability of
the resistant cells after exposure to radiation. It would also be useful to calibrate the
model for other types of cancers so as to explore the alterations in cellular heterogeneity
due to fractionated radiotherapy for various cancers with different characteristic behav-
iors. Furthermore, the model can be extended to study the impact of immunotherapy on
radiotherapy performance.
The effects of both plasticity and random fluctuations on demographic factors and
ultimately on the TCP have also been studied. These works has been described in Chapters
4 and 5. The impact of arbitrary changes on tumor control probability has been investigated
for a single-cell-type population. This simple model can be extended, based on the CSC
hypothesis, to a hierarchical model consisting of CSCs and progenitors. The initial results
show the role of random alterations in birth and death rates for a two compartment model
on the TCPS has the same impact as that reported in Chapter 4. It would be useful and
interesting to understand the impact of these changes on the TCPS+P . In addition, the
existence of plasticity among cancer cells results in an increase in the number of resistant
cells in tumors. Thus, the effect of random changes in transition rates from non-CSCs to
CSC states on the overall TCP merits further exploration. It might also be worthwhile
to explore the impact of random spatial changes on the hypoxic and normoxic regions of
tumors.
The impact of negative regulatory feedback on the sphere formation capacity of a single
CSC was considered in Chapter 6. Extending the model to include mature cells would
facilitate studying the changes that occur in SFE and AVSS due to the negative feedback
secreted from mature cells and controlling CSC and progenitor division. Moreover, it is
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important to investigate the sphere formation potential of a single CSC when mature cells
escape from the negative feedback control that regulates the plasticity rate between either
mature cells and progenitors or mature cells and CSCs.
7.2.2 Second cancers
Fractionated radiotherapy uses high doses of radiation to destroy cancer cells. It is an
important part of cancer treatment and may contribute to an increase in the number of
survivors; however, it is a double-edged sword and this regimen can cause complications.
For instance, second cancers are among the possible late side effects of radiotherapy and
can arise in organs nearby the original tumor. Developing a second cancer as a result of
this treatment is an increasing concern, especially among younger survivors. Therefore,
it is clearly of importance to study the risks of second cancers in patients treated with
radiotherapy. A comprehensive study on atomic bomb survivors approximately correlated
the cancer risk from exposure to intermediate doses of radiation; however, there is not much
understanding of the effects of higher doses. The latency period between radiotherapy and
the evolution of second cancers is long, so it takes significant time to monitor survivors
carefully and also to provide good epidemiological data in order to explore new treatment
regimens. These difficulties highlight the importance of model-based predictions.
A cascade of complicated biological mechanisms underlie the initiation and growth
a second cancer in an organ. These underlying processes make it hard to introduce a
practical measure for estimating the cancer risk. Therefore, applying a well defined and
quantitative approach that accurately measures the cancer risk is crucial and necessary.
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The year-specific excessive relative radiation risk (ERR) is a quantity that estimates by
how much the risk for people who received radiotherapy exceeds the risk of non-exposed
people over a specific period of time (Angell et al., 2009). The ERR is mathematically
calculated for intermediate and high doses of radiation, and shows that the second cancer
risk increases for patients treated for Hodgkin’s lymphoma (Sachs et al., 2005). This model
is implemented based on clonal evolution theory, and all the cancerous cells are assumed
to be able to proliferate equally. It would be interesting to extend the model based on the
CSC hypothesis and the existence of heterogeneity among cancer cells, so as to account for
their differences in proliferation potentials and DNA repair mechanisms.
In addition, the dose-volume data, which shows the relation between radiation dose
and tissue volume, is available experimentally and reported as a dose-volume-histogram
(DVH). Hence, the organ specific ERR can also be evaluated by applying the data to the
model (Hodgson, 2007; Zhang et al., 2015). However, a dose volume histogram does not
provide enough information about the distribution of the dose in the tissue. Consequently,
further work is needed to understand the effects of various cases of dose absorption in the
tissue. Such work would assess the organ specific ERR for the same dose volume histogram
data and so determine the effects of different dose distributions.
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Approximately 40% of cells go for repair
Figure A.1: The number of cancer cells NS+NP and the fraction of resistant cells NS/(NS+
NP ) for the radiotherapy schedules reported in Table 3.5 when approximately 40% of cells
undergo repair mechanisms.
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Approximately 80% of cells go for repair
Figure A.2: The number of cancer cells NS+NP and the fraction of resistant cells NS/(NS+

































Figure A.3: The number of cancer cells NS + NP for the Accelerated hyperfractionated
and the Hypofractionated protocols when the function g(d) is assumed to be proportional
to the inverse square of dose, inverse of dose, and a constant value 1.
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Approximately 90% of cells go for repair
Figure A.4: The number of cancer cells NS+NP and the fraction of resistant cells NS/(NS+
NP ) for the radiotherapy schedules reported in Table 3.5 when function g(d) is assumed
to be proportional to the inverse of dose.














































Approximately 90% of cells go for repair
Figure A.5: The number of cancer cells NS+NP and the fraction of resistant cells NS/(NS+
NP ) for the radiotherapy schedules reported in Table 3.5 when function g(d) is assumed
to be proportional to a constant value 1.
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Clinical trials schedules (40% of cells go for repair)
























Clinical trials schedules (40% of cells go for repair)
Figure A.6: The number of cancer cells NS+NP and the fraction of resistant cells NS/(NS+
NP ) for the radiotherapy schedules reported in START trials when approximately 40% of
cells undergo repair mechanisms.
Clinical trials schedules (90% of cells go for repair)
Clinical trials schedules (90% of cells go for repair)
Figure A.7: The number of cancer cells NS+NP and the fraction of resistant cells NS/(NS+
NP ) for the radiotherapy schedules reported in START trials when function g(d) is assumed
to be proportional to the inverse of dose.
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Clinical trials schedules (90% of cells go for repair) Clinical trials schedules (90% of cells go for repair)
Figure A.8: The number of cancer cells NS+NP and the fraction of resistant cells NS/(NS+
NP ) for the radiotherapy schedules reported in START trials when function g(d) is assumed
to be proportional to a constant value 1.
Figure A.9: The number of cancer cells NS + NP for the 50 Gy, 25 fractions (START A,
B) and the 40 Gy, 15 fractions (START B) protocols when the function g(d) is assumed




The extinction probability at time t, can be defined as TCP(t) = U(0, t). Assuming
U(z(τ), t(τ)) is constant along the characteristic curve C : [z(τ), t(τ)], we obtain the fol-
lowing ordinary differential equation
dz
dt
= −(z − 1)((z − 1)ρ(t) + β(t)) = 0. (B.1)
Considering the initial condition t(0) = 0, U(z(τ), t(τ)) = U(z(0), 0) along the charac-
teristic curve. The final purpose of radiotherapy is to achieve zero cells remaining in the
system at some time t = t∗. As a result, to compute TCP at time t = t∗, the characteristic
curve z(t∗) = 0 should be considered. Thus, TCP(t∗) = U(z(0), 0) in which z(0) is deter-
mined solving differential equation B.1 with the final value condition z(t∗) = 0. Taking
t → t∗ − t changes the final value problem into an initial value problem. Finally, TCP(t)
is obtained by solving the ordinary differential equation B.1 and substituting the solution
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The time evolution of chemical systems can be studied using both deterministic and
stochastic approaches. Deterministic models describe the behavior of the system using
differential equations, but for small populations or in the presence of randomness, stochas-
tic models can provide a better description of the evolution of species using a master
equation (Erban et al., 2007). Although solving master equations is often challenging,
stochastic formulations can be solved numerically using the Gillespie algorithm.
The Gillespie algorithm is a Monte Carlo type method that samples from a probability
distribution that captures the underlying mechanisms governed by the master equation.
Consider a system of N molecular species {S1, ..., SN} in a well-mixed population that
undergoes M reactions {R1, ..., RN}. The purpose of the algorithm is to find the state
vector X(t) = [ X1(t), ..., XN(t)] given the initial condition X(t0) = x0, where Xi(t)
denotes the population size of species i at time t. The number of any particular species
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varies when they go through any of the reactions Rj, j = 1, ...,M , which are defined by a
state change vector vj = (vij, ..., vNj) (vij is the change in the number of molecular type Si
induced by an event Rj) and the propensity function aj(x). Morover, aj(x)dt represents
the probability of the reaction Rj being initiated in the time interval [ t, t + dt), given
X(t) = x.
Assuming that all the reactions are separated events, the main strategy in this simula-
tion method is to generate the trajectory of X(t) starting from an initial state X(t0) = x0
by repeatedly finding the next time step τ and the next reaction µ (Cao et al., 2004; Gille-
spie, 2007). These two quantities are randomly determined following the distributions of
the next time step τ and the next reaction µ.
Let p(τ = s) denote the probability density that one of the reactions Rj, j = 1, ...,M
occurs in an interval (t + s, t + s + ds). Thus, p(τ = s) = p0(s)a0(x), where p0(s) is the
probability of having no reaction during (t, t+ s), and a0(x) displays the probability that
one of the possible M reactions fires at (t+ s, t+ s+ ds) with a0(x) =
M∑
j=1
aj(x). It can be
shown that p0(s) = exp(−a0(x)s), which indicates that the next time step τ given X(t) = x
is chosen from the exponential distribution p(τ = s) = a0(x) exp(−a0(x)s) with mean 1a0(x)
(Cao et al., 2004; Gillespie, 2007). The next reaction µ is also selected randomly with




One basic formulation of the Gillespie algorithm is the direct method, which generates
two random numbers r1 and r2 from the uniform distribution U(0, 1). In this framework,













aj(t) > r2a0(t). (C.2)
Thus, the number of species at each time step X(t) is calculated by applying the following
stochastic algorithm.
• Let t = 0 and X(0) = x0 (initialization)
• Evaluate propensity functions aj(x) and a0(x) at state X(t).
• Calculate τ and µ by generating random numbers r1 and r2 from the unit interval
uniform distribution and employing equations C.1 and C.2.
• Update time t← t+ τ and the status of species X ← X + νµ.
• Go to the second step or end the simulation.
The direct method has been improved and modified into other formulations (Cao et
al., 2004; Gillespie, 2007; Lu et al., 2004). One alternative to the direct method is the first
reaction method, which generates values of τ and µ differently. In this approach, a τj is








) (j = 1, ...,M), (C.3)
where r1,...,rM are M arbitrary numbers produced from the uniform distribution U(0, 1).
Consequently, the next time step is given as
τ = min{τ1, ..., τM}, (C.4)
and the next reaction µ corresponds to the index of the selected τj, j = 1, ...,M . Thus,
µ = the index related to the min{τ1, ..., τM}. (C.5)
Accordingly, the first reaction method algorithm is designed by changing the second and
third steps in the direct method approach as below
• Calculate propensity functions aj(x) at state X(t).
• Evaluate τj for each reaction using equation C.3 by generating r1, ..., rM random
number from the uniform distribution U(0, 1).
• Compute τ and µ applying derivations C.4 and C.5.
The two procedures discussed above are valid for time independent propensity func-
tions aj(x), j = 1, ...,M . However, the propensity functions can change continuously and
discontinuously over time to account for extrinsic and intrinsic fluctuations in the system.
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In this direction, Shahrezaei et al. (2008) developed a modified version of the Gillespie al-
gorithm to take into account time varying discontinuous propensity functions. Therefore,
assuming a discontinuous propensity function a(t) as below
a(t) =

a < (t) for t < t0,
a > (t) for t > t0,
the simulation time t is set to t0 if the next reaction time τ or the current time is larger
than t0 and a(t) is changed respectively. Hence, the algorithm is given by:
• Let t = 0 and X(0) = x0 (initialization)
• Calculate propensity functions aj(x) at state X(t).
• Evaluate τj for each reaction using equation C.3 by generating r1, ..., rM random
number from the uniform distribution U(0, 1).
• Compute µ applying equation C.5.
• If t + τµ < t0, update time t ← t + τµ and the status of species X ← X + νµ. If
t+ τµ > t0, change the propensity function a(t) and set t = t0.
• Go to the second step or end the simulation.
The direct method and the extended Gillespie algorithm for discontinuous reaction




Figure D.1: The tumor control probability when death rate is switching randomly, with





Figure D.2: Tumor control probability when death rate is switching randomly, with average
Γ = 1, ρ = 0.5, n0 = 50, and different standard deviations for switching rates ν = 0.02 and
ν = 0.2.
Figure D.3: The average extinction tome and extinction time distribution when Γ = 1,
n0 = 50, ρ = 1, and different standard deviations for switching rates ν = 0.02.
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Figure D.4: The average and variance of cell numbers with n0 = 50, Γ = 1, ρ = 0.5, and
different standard deviations for switching rate ν = 0.02.
Figure D.5: Tumor control probability obtained from analytical solution with Γ = 1,
ρ = 0.5, σ = 0.4, and n0 = 50.
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Figure D.6: The average and variance of cell numbers with n0 = 50, ρ = 0.5, Γ = 1, and
different standard deviations for switching rate ν = 0.02.
Figure D.7: The average and variance of cell numbers with n0 = 10, Γ = 0.5, ρ = 0.5, and
different standard deviations for switching rate ν = 0.02.
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Figure D.8: The average and variance of cell numbers with n0 = 10, Γ = 0.5, ρ = 0.5, and
different standard deviations for switching rate ν = 0.02.
Figure D.9: The average and variance of cell numbers with n0 = 10, Γ = 0.5, ρ = 0.5, and
different standard deviations for switching rate ν = 0.02.
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Figure D.10: Extinction probability obtained from analytical solution with ρ = 0.5, Γ =
0.5, σ = 0.2, and n0 = 10.
Figure D.11: Extinction probability obtained from analytical solution with ρ = 0.7, Γ =




The stochastic dynamic of model 5.1 in the absence of plasticity (i.e. ρPS = 0) can
be explained using the following master equation showing the probability of having a
population of nS stem cells and nP progenitors with the initial number of cells nS0 and
nP0 at time t0.
dpnS ,nP (t)
dt
= ρS(nS − 1)pnS−1,nP (t)− ρSnSpnS ,nP (t) + ρSP (nS + 1)pnS+1,nP−1(t)
− ρSPnSpnS ,nP (t) + ρP (nP − 1)pnS ,nP−1(t)− ρPnPpnS ,nP (t) + ΓS(t)(nS + 1)pnS+1,nP (t)
− ΓS(t)nSpnS ,nP (t) + ΓP (t)(nP + 1)pnS ,nP (t)− ΓP (t)nPpnS ,nP (t).
(E.1)
The initial condition is given next with δi,j representing the Kronecker delta function:
pnS ,nP (t0) = δnSnS0δnPnP0 . (E.2)
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Using the probability distribution function introduced above, we can define the marginal





with the following master equation
dunS(t)
dt



















Figure F.1: (a) TCPS and (b) TCPS+P for standard, hyperfractionated, and accelerated
hyperfractionated schedules with different dedifferentiation rates ρPS, between non-CSCs
and CSCs. The initial numbers of cells are n0S = 100 and n
0
P = 100.
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